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v 
Preface 
Presented in this thesis are the results obtained from the project: Asymmetric synthesis 
of substituted 2-aminotetralins. The initial goal was to establish new or improved routes 
to enantiopure 2-aminotetralin (2-AT) derivatives. The motivation for this project was 
based on the diverse applications various 2-ATs represent as biologically active 
compounds. Despite the role of 2-aminotetralins as interesting target molecules, 
reflected by the massive research activity in the field, no general and cost efficient route 
has really been established.         
 
Chapter 1 in this thesis gives an introduction to 2-ATs as biologically active 
compounds, as well as a brief survey of the concepts of chirality and asymmetric 
synthesis. Aziridines are also presented, given their role as key intermediates in our 
developed strategies (chapters 2-4). 
 
In chapter 2, a total synthesis of substituted (S)-2-ATs is presented, starting from natural 
L-aspartic acid. Two 2-AT derivatives were successfully synthesised, but especially one 
step (ring-closing to tetralones) proved difficult, providing up to 41% yield only.       
 
Chapter 3 is directly based on the experiences we made in the former chapter, and 
presents an improved route from the same starting point (chiral pool strategy utilising L-
aspartic acid). Again we struggled with one specific cyclisation reaction (up to 36% 
yield), but the remaining steps provided overall good yields.   
 
In Chapter 4, a different approach has been targeted, i.e. asymmetric aziridination of 
1,2-dihydronaphthalenes. Here, various copper, rhodium and ruthenium catalytic 
systems were tested with alternative nitrogen sources. While we were able to achieve 
quite good results for non-substituted 1,2-dihydronaphthalene, substituted substrates 
provided only mediocre yields and enantioselectivity. Aziridines were selectively ring-
opened by catalytic hydrogenation to their respective N-protected 2-ATs in good yields.      
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1 Introduction 
1.1 Background 
1.1.1 Chirality and asymmetric synthesis 
Chirality is a fundamental property of three-dimensional objects. An object is chiral if it 
cannot be superimposed on its mirror image. In such cases, the two possible forms are 
referred to as enantiomers.1  Chirality is of prime significance, as most biological 
macromolecules of living systems occur in nature in one enantiomeric form only. Like 
the natural L-amino acids, 19 of the 20 (one achiral) are chiral building blocks for 
proteins and enzymes.2a Likewise, sugars represent a group of natural compounds with 
well defined stereochemistry.2b The respective enantiomers of a biologically active 
chiral compound will interact differently with chiral receptors in organisms, with 
potentially dissimilar responses. For example, the natural amino acid (S)-aspargine is 
bitter, while its unnatural counterpart has a sweet taste.3 And where one enantiomeric 
form of benzopyryldiol is considered to be highly carcinogenic, the other is inactive 
(examples demonstrated in Figure 1.1).4  
 
Figure 1.1: Examples of diverse enantiomeric characteristics 
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Keeping this in mind, it should be no surprise that chiral drugs today should be 
investigated and approved in the form of pure enantiomers, rather than as a racemic 
mixture. This is also one of the key reasons for the enormous effort that has been put 
into the development of new improved methods to synthesise enantiopure products, 
often referred to as asymmetric synthesis.   
 
So – what is an asymmetric synthesis? There are various definitions present in the 
literature, e.g. the commonly quoted one by Marckwald,5 and most appear to be quite 
cumbersome to state. This is mostly because of technical concerns regarding 
asymmetric induction and asymmetric reactions, as well as discussions about 
limitations. For the purpose of having a simplified and easy to handle definition, a 
representative textbook6 uses the following: An asymmetric synthesis is one which 
creates new stereogenic units in a controlled way. The very same source also states that: 
Nowadays, when we refer to asymmetric synthesis, we generally mean one which is 
capable of giving rise to enantiopure products. Taking the latter statement into 
consideration, we might as well include classical resolution of racemic mixtures and 
chiral pool synthesis to the concept of asymmetric synthesis. However, looking back to 
the prior statement, no new stereogenic unit is really formed. Anyway, if we focus on 
the “true” and indisputable asymmetric syntheses, where new stereogenic units are 
created, they can be classified according to how the chiral influence is exerted:7  
 
I – Substrate-controlled methods (First-generation asymmetric synthesis) 
Diastereoselective reactions where the formation of a chiral centre is controlled by 
another chiral centre already present in the substrate.   
 
II – Auxiliary-controlled methods (Second-generation) 
Methods where a chiral auxiliary is covalently attached to the substrate and, through 
that, controls the asymmetric induction. This strategy, with intramolecular controlled 
induction, is basically the same in first- and second-generation methods. The difference 
is the attachment and removal of the auxiliary in the latter.     
  
  
Chapter 1 – Introduction 
 
3 
III – Reagent-controlled methods (Third-generation) 
The formation of a new chiral centre is induced by a chiral reagent or catalyst, 
intermolecularly.    
 
IV – Catalyst-controlled methods (Fourth-generation) 
Catalytic modifications of the first-, second-, and third-generation methods tend to be 
considered together with this new fourth-generation. One general procedure involves a 
reaction of a chiral substrate with a chiral reagent, and is especially useful in reactions 
where two new stereogenic units are formed stereoselectively in one step. The most 
significant advance in asymmetric synthesis in the past three decades has however been 
the application of chiral catalysts capable of making chiral products from achiral 
substrates. 
 
A simplified overview of the various generations of asymmetric synthesis is shown in 
Figure 1.2. 
Substrate* Product*Reagent
Auxiliary*
Catalyst*
First-generation:
Second-generation:
Third-generation:
Fourth-generation:
S-A* P-A* Product*ReagentSubstrate + Auxiliary*
Substrate Reagent* Product*
Substrate*
Substrate
Product*
Product*
Reagent*
 
Figure 1.2: Generations of asymmetric synthesis (chirality displayed by *-symbol) 
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1.1.2 2-Aminotetralins- pharmacologically active compounds 
Before the introduction of this class of compounds, we should discuss the basic 
structure of 2-aminotetralin. Tetralin might be considered as a partly hydrogenated 
naphthalene compound, where one ring is aliphatic and one is aromatic (Figure 1.3). 
Correct naming of such a ring system, according to IUPAC rules,8 is in fact 1,2,3,4-
tetrahydronaphthalene. Tetralin, however, is a common trivial name used in the 
literature. 
 
 
Figure 1.3: Tetralin and 2-aminotetralin, structures and IUPAC-names. 
 
The pharmacological activity of 2-aminotetralin was first described by Bamberger and 
Filehne back in 1889.9 Since then, a range of 2-aminotetralin (2-AMT) compounds have 
been found to possess pharmacological effects on the nervous system of the mammalian 
body, by binding selectively to serotonin (5-HT)10-12 and dopamine (DA)13-16  receptors, 
exerting agonist or antagonist activity. In several psychiatric diseases like anxiety, 
depression and schizophrenia, which are thought to be dysfunctions in the 
monoaminergic neuronal system, development of therapeutically useful 2-
aminotetralins have emerged.17-19 Various analogues are also known to show activity 
against adrenergic receptors20 and antagonist activity at -opioid receptors.21  
 
To emphasise the structural similarity between 2-AMTs and other compounds with 
similar activity, let’s take a look at some well known dopamine agonists. Figure 1.4 
demonstrates the structural resemblance between dopamine itself and three known 
agonists, including a specific 2-AMT derivative with well documented activity.15,22,23 
What they all have in common is a 2-phenylethylamine moiety (illustrated in bold), 
either in a conformational flexible structure, or as a part of a rigid multi-cyclic 
molecule.   
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HO
HO
NH2
N
Dopamine
FenoldopamN ,N -Di-n-propyl-5,6-dihydroxy-2-AMT
HO
N
CH3
OH
H
R-(-)-Apomorphine
n-Pr
n-Pr
HO
OH
NH
HO
HO
Cl
HO
 
Figure 1.4: Dopamine and dopamine agonists 
 
To highlight the importance and the diverse applications of 2-AMTs in the recent years, 
representative examples are shown in Figure 1.5.  
 
The chiral (S)-2-AMT drug Rotigotine is a non-ergotamine dopamine agonist, recently 
implemented in the treatment of Parkinson’s disease.24 The drug is delivered to the 
patient through transdermal patches, resulting in a constant level of dopamine in the 
blood and brain. This is considered to be a huge improvement compared to traditional 
levodopa pill treatment, which results in unfortunate fluctuation of the patient’s 
dopamine level. Septic shock is a clinical syndrome which might occur from severe 
infections caused by bacteria, protozoa or by viruses. For the treatment, several 6,7-
disubstituted 2-AMTs have been evaluated, and among them, especially racemic-2-
amino-6-fluoro-7-methoxytetraline was found to be active.25 Later studies have revealed 
that (S)-2-amino-6-fluoro-7-methoxytetraline is far more potent than the racemate.26-28 
Glaucoma, sometimes nicknamed “the sneak thief of sight”, is a disease that affects the 
optic nerve. In the treatment, N-methyl-5,6-diisobutyroyloxy-2-AMT has been 
implemented.29 Evaluation of the drug revealed that the (S)-enantiomer is about twice as 
selective as the racemate towards pre-synaptic 2-adrenoceptors and dopamine D2-
receptors. A range of N-alkylated 2-amino-6,7-dimethoxytetralins have demonstrated 
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pharmacological activity as antihypertensive agents. However, the activity tests reported 
in the literature only refer to racemates in this context.30 In the treatment of obesity, 
amphetamines have been enlisted for the purpose of inducing weight loss, but 
undesirable side effects have led to search for more specific dopamine agonists.31 
Various 2-AMTs, especially their S-enantiomers, have been evaluated for this purpose. 
Among these, derivatives of (S)-2-amino-7-methoxytetralin have been applied as active 
compounds in diet pills.32   
 
 
 
Figure 1.5: Examples of pharmacologically active 2-AMTs used in various treatments 
 
In an in vivo study of the respective enantiomers of N,N-di-n-propyl-5-hydroxy-2-AMT, 
it was discovered that the S-enantiomer is a very potent D2-receptor agonist. On the 
other hand, the R-enantiomer was found to be a weakly potent antagonist.33 
 
To summarise according to the examples above (Figure 1.5), it appears to be a general 
preference for the S-enantiomer of 2-AMTs when concerning their pharmacological 
activity. But in some cases, no enantiomeric preference has been discovered, or even 
studied, thus racemic mixtures are utilised.  On the other hand, there are indeed a few 
striking examples of a strong preference for the specific R-(+)-2AMT enantiomer. One 
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example is the very potent serotonin 5-HT1A agonist (R)-(+)-N,N-di-n-propyl-8-
hydroxy-2-AMT (8-OH-DPAT), which has become the ligand of choice in binding 
experiments within this receptor subclass.34 Another example is (R)-(+)-N,N-di-n-
propyl-7-hydroxy-2-AMT (7-OH-DPAT), which has been found to be a highly selective 
dopamine D3 -ligand.35 As a conclusion, we might say that these examples underscore 
the importance of synthesising such compounds in their pure enantiomeric form.     
 
1.1.3 Aziridines as key intermediates 
Since aziridines play a crucial role as key intermediates in the strategies presented in 
this thesis, a brief introduction is given herein.    
 
Structure, physical and biological properties 
Aziridines are structural units consisting of a three-membered nitrogen heterocycle with 
an amino group and two methylene groups. The bond angles in the ring are 
approximately 60º, which is much less than the regular 109.5º angle in sp3-hybridised 
hydrocarbons. This is comparable to epoxides and cyclopropanes, which also share this 
strained three-membered ring structural characteristic (Figure 1.6).36  
 
 
Figure 1.6: The general structure of aziridines 
 
The bonds are considered to be somewhat bent, and thereby also known as “banana 
bonds”. To assume this strained structure, an increase in the p-character is needed for 
the ring bonds, with the consequence of a higher degree of s-character on the C-R 
bonds, hence making them shorter.37 The angle strain in aziridines also results in higher 
energy barriers for nitrogen inversion, i.e. pyramidal (or “umbrella”) inversion, which is 
extremely rapid in flexible aliphatic amines. As a result, stable aziridine invertomers can 
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actually be physically separated in special cases.38 Interestingly, this particular motion 
has recently also been investigated for the purpose of developing molecular switches in 
nanoscale devices.39   The structural consequence of the ring also results in lowered 
basicity of aziridines compared to aliphatic amines, which is due to the increased s-
character for the nitrogen lone pair in aziridines  (aziridine pKaH 7.940 and e.g. 
diethylamine pKaH 10.941).  
 
Aziridines occur in several natural products which have been found to possess valuable 
properties in medicinal chemistry. Mitosanes (Mitomycins) are a well known class of 
compounds that demonstrates anticancer and antibiotic effects.42,43 Two other families 
of anticancer natural products are Azinomycins44,45 and the PBI (pyrrolo[1,2-
a]benzimidazole) class.46 Examples of synthetic aziridines with similar properties are 
triethylenemelamine (anticancer)47,48 and 1-alkoxy-2-aziridinephosphonates 
(antibiotic).49 The structures of some of these biologically active aziridines are shown in 
Figure 1.7. 
 
 
Figure 1.7: Biologically active aziridines with anticancer properties 
 
Synthesis of aziridines 
During the last decades, several review articles concerning aziridine synthesis have 
emerged.50-53 One way of classifying these reactions are by their respective precursors. 
Three major classes of precursors are presented below, illustrated with specific 
examples: 
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I) From 1,2-amino alcohols (Wenker type synthesis54)  
By converting the hydroxyl group into a good leaving group (typically sulfonates), the 
amine lone pair or the amide anion can cause an intramolecular displacement reaction. 
A specific two step procedure is shown below (Scheme 1.1), demonstrating the 
synthesis of a vinylaziridin.55 
 
 
Scheme 1.1 
II) From epoxides (azide ring opening and Staudinger reduction)  
Ring opening reactions of epoxides with an azide followed by a Staudinger reduction56 
with triphenylphosphine proceeds via different intermediates to aziridines. A specific 
example published by Tanner and Somfai57 is shown in Scheme 1.2: 
 
 
Scheme 1.2 
III) From alkenes (nitrene addition or the Gabriel-Cromwell reaction)  
Asymmetric aziridinations via nitrene transfer to alkenes, by means of transition metal 
catalysts, will be thoroughly presented in Chapter 4.  
 
A range of chiral derivatives of -bromoacrylates undergo reactions with amines to 
yield chiral aziridines. An example of this auxiliary mediated diastereoselective 
Gabriel-Cromwell reaction is presented below (Scheme 1.3).58  
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N
O2S
O
N
O2S
O
Br
N
O2S
O
Br
N
N
O2S
O
N
Bn
COOMe
N
Bn
HS
i) Br2
ii) Et3N BnNH2
68% total yield
(98% ee)
SN2
N-Acryloyl camphor sultam
H
N
O2S
O
Br
NHBn
H
Bn
H
si-face
protonation
Mg(OMe)2
MeOH, rt
 
Scheme 1.3    
 
 
Ring-opening reactions 
The ability of aziridines to undergo highly regio- and stereoselective ring-opening 
reactions makes them interesting synthetic building blocks with great synthetic   
value.59-61 Numerous nucleophiles can successfully perform such reactions. Only a brief 
introduction to carbon nucleophiles will be given here based on their relevance for this 
project. 
 
Ring-opening of aziridines by carbanion species results in the formation of new carbon-
carbon bonds and, through that, considerable attention has been attracted.59   Aziridines 
are considered to be relatively non-reactive electrophiles, and require activation to 
perform ring-opening reactions with good regio- and stereo control.60 Activation is 
performed by the introduction of an electron withdrawing group (EWG) on the aziridine 
nitrogen, and thereby giving rise to stabilisation of the negative charge present in the 
transition state. This is primarily due to the inductive effect, but with N-carbonyl 
substituents, a thermodynamic resonance stabilisation of the intermediate anion also 
contributes.51 Examples of such EWG-groups, which also serve as amine protective 
groups are acyl, carbamate or sulfonate functionalities. Among the various alkyl metal 
reagents used in these reactions, soft organocopper species have very often been 
preferred since they tend to provide good chemoselectivity.62-64  Hard organolithium 
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and organomagnesium (Grignard) reagents have also been reported to work satisfactory 
in some cases.65-67 However, they are considered to be less chemoselective and are, due 
to their higher reactivity, more prone to react with the protecting group or other 
substituents present in the substrate. In a representative example below, various tosyl 
protected aziridines are regioselectively ring opened (Scheme 1.4).68  
 
 
Scheme 1.4 
 
 Application of Lewis acid catalysis broadens the scope even more. Examples for 
selective ring-opening reactions of non-activated aziridines with Gilman cuprates 
(R2CuLi), catalysed by BF3-etherate, have been reported.69  
 
 
1.2 Objectives and strategies of this project 
The literature concerning 2-aminotetralin derivatives is massive70 and the main reason 
for this can be explained by the diversity this class of compounds represents. As active 
agent in various drugs and therapeutic remedies, pharmaceutical companies require 
efficient and reliable methods for their production. And obviously – with cost efficiency 
as a key factor as well.  
 
In this project, our objective was to improve or design methods to synthesise 
enantiopure 2-aminotetralins. The methods were also designed with the intension to be 
relatively general, and capable of synthesising several analogues of substituted 2-
aminotetralins.  
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Two main approaches towards enantiopure 2-aminotetralins have been targeted in this 
project: 
 
Chiral pool approach  
The cheap and readily available L-aspartic acid was chosen as the chiral source (Scheme 
1.5). In chapters 2 and 3, the results of two different total syntheses of substituted (S)-2-
aminotetralins are presented. These chapters have served as basis for two papers (Paper 
I and II for chapter 2 and 3, respectively).   
 
 
Scheme 1.5 
 
 
Asymmetric catalysis approach    
Preparation and testing of new catalytic systems for catalysing asymmetric 
aziridinations  of alkenes (1,2-dihydronaphthalenes) has been attempted (Scheme 1.6). 
The results are presented in chapter 4, as well as in Paper III. 
 
Scheme 1.6 
 
Each chapter initially presents relevant background information, covers relevant 
knowledge and presents the current status in the specific areas. Finally, a summary of 
the results is given with some comments on the potential and future perspectives.        
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2 Chiral pool synthesis of 2-aminotetralins– Part I 
2.1 Background 
In this chapter we present a brief overview of the main synthesis of 2-aminotetralins 
known from the literature.  
 
Optical resolution 
Several examples of resolution of various precursors in the synthesis of enantiopure 2-
aminotetralins have been reported.71-73 Resolution of racemic 2-aminotetralins is also 
well documented.74,75   
 
Chemoenzymatic synthesis  
Through various chemoenzymatic protocols (R)-8-methoxy-2-AMT76 and (S)-7-
methoxy-2-AMT77 have been successfully produced. In a publication by Martin and co-
workers, aminotransferases are utilised in the synthesis of enantiopure 2-
aminotetralins.78     
 
Catalytic hydrogenation of enamines, enamides and ene carbamates 
Another common synthetic route to 2-aminotetralins starts from -tetralones. By 
reacting them with amines or amides, followed by a subsequent dehydration step, 
enamines or enamides are formed, respectively (for example of the latter, see Scheme 
2.1). Catalytic hydrogenation of such systems results in racemic 2-aminotetralins, which 
have been known for several decades.79 Since the turn of the millennium, a range of 
chiral hydrogenation catalysts have been reported to produce enantioenriched 2-
aminotetralins. However, very often low conversion and/or low to mediocre 
enantioselectivity was obtained. Most of these chiral catalysts are either ruthenium80-82 
or rhodium83-85 based, and a broad range of ligands have been investigated. As the 
common benchmark substrate, N-(3,4-dihydro-2-naphthalenyl)acetamide has often been 
chosen in the evaluation of these asymmetric hydrogenations  (Scheme 2.1). 
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Scheme 2.1 
 
Exceptionally good results for this transformation have been obtained through recent 
advances in supramolecular catalysis.86 The benchmark reaction (Scheme 2.1) was 
shown to proceed with full conversion and high enantioselectivity (94% ee) by applying 
a specific supraphos ligand (Figure 2.1). The authors of this publication point out the 
importance of a large library screening, which in their case resulted in only one 
successful out of 64 supraphos ligands tested.   
 
 
Figure 2.1: Construction of the successful rhodium catalyst with bidentate supraphos 
ligand. The nitrogen donor atom reversibly coordinates to zinc, and thereby creates the 
bidentate supraphos ligand, which in turn can coordinate to the rhodium metal.   
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Chiral pool synthesis from natural amino acids    
In a recent publication by Quiclet-Sire and co-workers, L-phenylalanine and L-tyrosine 
serve as chiral building blocks in the synthesis of rare 4-substituted 2-aminotetralins.87 
Utilisation of L-aspartic acid has also previously been reported.88,89 The basis for this 
strategy is the formation of an N-protected aspartic anhydride derivative. This cyclic 
anhydride is prone to react with a nucleophilic aryl compound, catalysed by a Lewis 
acid. Followed by a sequence of reductions, cyclisation and N-deprotection, 2-
aminotetralins are produced. In the earliest example, published by Zymalkowski and 
Dornhege, a phthalyl group serves as the N-protecting group (Scheme 2.2).89 
O
PhthN
O
O
PhthN
COOH
O
L-Aspartic acid
70% 81%
i) N -Ethoxycarbonyl-
phtalimide
ii) DCC
PhthN
COOH
H2/Pd
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92%
PhthN
O 85%
H3N
48%
PhthN
91%
Cl
H2/Pd
HCl
AlCl3
Benzene
N
O
O
= PhthN
   
Scheme 2.2 
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In a procedure published by Nordlander and co-workers (Scheme 2.3),88 a 
trifluoroacetic anhydride is initially formed as the chiral synthon (method published 
earlier by Lapidus and Sweeney 90). 
O
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H
N COOHVeratrole
AlCl3
O
F3C
Et3SiH
O
OCH3
OCH3
H
N COOH
O
F3C
OCH3
OCH3
i) PCl5
ii) SnCl4
OCH3
OCH3
O
H
N
O
F3C
Et3SiH
OCH3
OCH3
H
N
O
F3CBF3.Et2O OCH3
OCH3
H2NK2CO3(aq)
55%
72% 80%
85% 46%
L-Aspartic acid
TFAA
98%
N -Trif luoroacetyl acetic anhydride
Scheme 2.3 
 
This methodology has served as the basis for a range of analogues, described in various 
patents and publications, which all utilise the N-trifluoroacetyl aspartic anhydride as the 
starting point.28,91-93 
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2.2 Retrosynthesis and target molecules 
In our attempt, we investigated the possibility of making an appropriate N- and C-
protected aziridine as the key intermediate, which could in turn be regioselectively 
opened by an aryl nucleophile. The strategy of our synthesis was based on the retro-
synthetic approach described in Scheme 2.4. 
COOHH2N
COOH
NH2
Substituted (S)-2-Aminotetralin
H
N
COOR
N
COOR
M
X
+
X
L-Aspartic acid
X = Amine protecting group
M = Metal
R
R
R
b c
d
H
N
COOR
X
a
OH
 
Scheme 2.4 
 
Initially, protection of the -carboxylic acid and the amino group of L-aspartic acid 
should be performed.  Then a reduction to an amino alcohol (a) makes the starting point 
in the transformation to aziridine (b). The key step, where the two synthons (b and c) 
are brought together, is the regioselective ring-opening of the protected aziridine (b) 
with an appropriate aryl nucleophile (c), resulting in the ring-opened product (d). In the 
final steps, an intramolecular cyclisation followed by a deoxygenation should then 
provide the 2-aminotetralins.  
 
With the goal to accomplish a general synthetic route, we decided to aim for four target 
molecules (27-30), differing only in the aromatic substituent pattern. As a consequence, 
the aryl reagent becomes the only variable for the reaction with the enantiopure 
aziridine. The specific target molecules 27-30 (Figure 2.2) were all chosen among the 
analogues relevant for pharmaceutical industry, i.e. molecules which are known to exert 
biological activity (see Chapter 1.1.2). 
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Figure 2.2: Target molecules  
 
The results from this work are described in the following chapter. 
 
2.3 Results and discussion 
2.3.1 Aspartic acid protecting groups 
A selective protection of the -carboxylic acid function of aspartic acid was required for 
the synthetic strategy. After some considerations, the protection group of choice became 
the tert-butyl ester. The bulky tert-butyl substituent not only protects the carbonyl 
moiety against nucleophilic attack, but also demonstrates resistance towards basic 
hydrolysis.94a Aspartic acid 4-tert-butyl ester (1) is commercially available, but it can 
also be synthesised through various protocols from cheap and readily available L-
aspartic acid, through e.g. esterification of its boron trifluoride complex.95 
 
Protection was also necessary for the amine function to suppress its nucleophilic 
character and to prevent racemisation during the course of the reaction.94f This 
protection group also needed to be stable under basic reaction conditions. Based on 
these requirements, three candidates were considered: tert-butyloxycarbonyl (Boc), 
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benzyloxycarbonyl (Cbz) and p-toluenesulfonyl (Ts). The two former are well known in 
peptide synthesis, among others for their ability to suppress racemisation.94f Introduction 
of a Boc or a Cbz protective group is straightforward, and deprotection can easily be 
achieved by acidolysis or catalytic hydrogenation, respectively.94b-c Compared to these 
two, the tosyl group is a more robust candidate, stable in both basic and acidic 
environment.94e The disadvantage of using N-tosylates is related to the deprotection 
step, where one-electron transfer reagents are required. Synthesis of N-tosylate 2b is 
presented in Scheme 2.5, while carbamates 2a and 2c are commercially available and 
were purchased. 
 
 
  Scheme 2.5 
 
2.3.2 Reduction to amino alcohols 
The reduction of the acids 2a-c were performed by a protocol involving a mixed 
anhydride intermediate as the objective of the sodium borohydride reaction.96 The 
isolated yields were typically in the range of 70–90% (Scheme 2.6 and Table 2.1), with 
the exception of acid 2b. The obvious advantages of this method were the very short 
reaction time and the mild reaction conditions. 
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Scheme 2.6 
Table 2.1: Reduction via mixed anhydride intermediate 
Entry X Acid Alcohol Yield (%) 
1 Cbz 2a 3a 89 
2 Ts 2b 3b -a 
3 Boc 2c 3c 78 
  a) Reduction of 2b failed to provide alcohol 3b. 
 
An efficient reduction of 2b failed to succeed under these conditions. Attempts with 
alternative solvent (DMF) or elevated temperature (room temperature), were also 
unsuccessful. Reduction by a combined sodium borohydride/iodine protocol, failed as 
well.97 Another rather sophisticated derivatisation attempt, involving the reduction of a 
benzotriazole intermediate, was also investigated. The substrate was synthesised 
according to Katritzkys protocol,98 and subsequently reduced according to Nain Singh 
and Kaur99 resulting in approx 20% yield of 3b. The reason for the low yield was 
primarily due to difficulties in the formation of the acylbenzotriazole substrate, and not 
the reduction itself. Borane reductions of 2b also proved to give low yields (<25%), 
even by using as much as 6 equivalents of the reducing agent. As a comparison, 
Stanfield and co-workers reported good yields (75-90%) for a series of Boc-protected 
amino acids by this methodology.100   
 
An alternative attempt to achieve alcohol 3b in an acceptable yield was performed by a 
deprotection–reprotection sequence from alcohol 3a. Catalytic hydrogenation over Pd/C 
and subsequent N-tosylation afforded the amino alcohol 3b in a total yield of 84% 
(Scheme 2.7).  
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Scheme 2.7 
Inspired by the fact that selective tosylation of the intermediate amino alcohol (Scheme 
2.7) reacted smoothly and provided a good yield, we decided to investigate the 
possibility of reducing ester 1, prior to N-protection. A borane/BF3-protocol for the 
reduction of L-valine to L-valinol was tested, but it proved to be destructive for the tert-
butyl ester function.101  
2.3.3 Ring-closing reactions to aziridines 
Our first consideration in the aziridine syntheses was to utilise a typical Wenker-type 
substrate,54 i.e. derivatisation of the alcohol function with a good leaving group. Initial 
attempts were performed by tosylation of N-Boc-amino alcohol 3c to tosylate 3c-Ts.102 
However, this compound failed to react to aziridine 4c when treated with various bases 
(Et3N, 2,4,6-dimethylpyridine, LiHMDS, NaH), and instead we observed the formation 
of oxazolinone 49 (Scheme 2.8).  
H
N
COOtBu
OTs
N
COOtBu
Boc
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3c-Ts (90% yield)
3c
4c
TsCl
pyridine
HN
O
O
COOtBu
49 (Up to 74% yield)
Boc
 
Scheme 2.8 
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Formation of oxazolinones from tosylated (or mesylated) N-Boc--amino alcohols, have 
previously been reported in the literature.103,104 This is also in accordance with the 
conclusion from Nakajima and co-workers, who reported oxazolinone formation as the 
major product from a range of O-tosylated N-acyl and N-carbamoyl protected amino 
alcohols.105 In a relevant example by Song and co-workers, compound 3a was 
mesylated under basic (diisopropylethylamine) conditions, but no aziridine 4a was 
reported to be formed.106   
 
Based on these results we decided to terminate this ring-closing strategy and turned our 
attention to the Mitsunobu-reaction,107,108 where several successful aziridination 
reactions have been reported.109-111 The advantages of this reaction are the mild reaction 
conditions, the short reaction times and the fact that it is a simple one-pot 
transformation. Aziridination of amino alcohols 3a-c was tested under various reaction 
conditions, utilising the classical diethyl azodicarboxylate (DEAD)/triphenylphosphine 
reagents (Scheme 2.9 and Table 2.2). 
 
 
Scheme 2.9 
Table 2.2: Aziridination under Mitsunobu-conditions 
Entry X Amino alcohol Aziridine Yield (%) 
1 Cbz 3a 4a 71a 
2 Ts 3b 4b 90a 
3 Boc 3c 4c 46b 
  a) 1.0 equiv DEAD/PPh3, 0 ºC, 5-6 h. b) 2.0 equiv DEAD/PPh3, rt, 1-2 h. 
 
A well known drawback concerning the Mitsunobu-reaction is the purification step. For 
many relatively polar products, it may be difficult to remove diethyl hydrazine 
dicarboxylate derivatives as well as triphenylphosphine oxide completely. Recent 
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advances concerning the Mitsunobu-reaction have been dealing with this, and 
successful attempts to perform the Mitsunobu-reaction with catalytic amounts of DEAD 
have been reported.112 The catalytic cycle works by using a stoichiometric amount of 
iodosobenzene diacetate (hypervalent iodine) as an oxidant for the hydrazine derivative. 
By utilising such a system, easily removable iodobenzene and acetic acid are formed 
together with triphenylphosphine oxide. The reported test system was an intermolecular 
esterification reaction (2 mmol scale) with 4-nitrobenzoic acid and 2-phenylethanol, 
yielding up to 90% of the products.  
 
H
N
COOtBu
Ts OH
N
COOtBu
Ts
EtO N N OEt
O O
EtO N
H
N
H
OEt
O O PhI(OAc)2
PhI +
2AcOH
PPh3O=PPh3
EtO N N OEt
O O
+ +
PPh3
diethyl azodicarboxylate
(DEAD)
3b 4b  
Scheme 2.10 
Inspired by the catalytic Mitsunobu-reaction, we decided to apply the reaction 
conditions to our intramolecular aziridination reaction (Scheme 2.10). Cyclisation of 
amino alcohol 3b was attempted because of the substrates high performance in the 
stoichiometric reaction (entry 2, Table 2.2). However, when the reaction was performed 
in a 0.3 mmol scale, only a stoichiometric amount of product 4b (based on DEAD) was 
isolated, indicating no catalytic effect.  
 
An alternative to the classical DEAD/triphenylphosphine-reagent in Mitsunobu-
reactions is the 1,1’-(azodicarbonyl)dipiperidine (ADDP)/tributylphosphine (TBP)-
system.113 While the former method required sufficiently acidic substrates (pKa <11) to 
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react (corresponds to X-NH-R acidity for 3a-d), the latter is reported to work even for 
less acidic groups (pKa 13). The difference in reactivity has been explained by three 
factors:113 i) Increased nucleophilicity of the applied phosphine (smaller substituents in 
PBu3 than PPh3). ii) Higher degree of positive charge on phosphorous in the 
intermediates (no aromatic delocalisation). iii) Intermediate azo-anion, responsible for 
the deprotonation of the acid, is more basic. To investigate if the ADDP/TBP-system is 
capable of improving the yield, we decided to test amino alcohol 3a (predicted pKa 
(H2O) = 11.33 ± 0.46)114 (Scheme 2.11). The isolated yield of N-Cbz-aziridine 4a was 
found to be 28%, which did not show any improvement compared to the previous 
attempts. Since both, 4a and 4b, were formed in good yields by the DEAD/PPh3-
system, we decided not to pursue any optimisation work.   
 
 
Scheme 2.11  
 
2.3.4 Regioselective ring-opening of aziridines 
After an evaluation of the two alternative carbamate protection (Cbz and Boc) 
strategies, we decided at this point to focus only on Cbz protected substrate 4a in the 
following part of the developing strategy. Based on this, Cbz-aziridine 4a and Ts-
aziridine 4b were chosen as substrates for the reaction with the various aryl 
nucleophiles. Both of them are considered to be activated aziridines, due to the EWG-
substituents on the nitrogen atom.  
 
For the synthesis of the four target molecules, we purchased the following substituted 
bromobenzenes: 3-bromoanisole (5), 5-bromo-2-fluoroanisole (6), 2-bromoanisole (7) 
and 4-bromoveratrole (8).   
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Initial reactions quickly revealed that stoichiometric control of the Grignard-reagent was 
crucial. To ensure controlled reaction conditions for the envisioned ring opening 
reactions, we needed a system for quantifying the Grignard-reagent. To do this, we 
implemented the protocol developed by Love and Jones, where salicylaldehyde 
phenylhydrazone is used as a titration indicator.115 Before the addition of freshly 
prepared Grignard-reagent to the aziridines, the concentration was determined by 
titration (typically 1.0-1.1 M). The results of the reactions between aziridine 4a and 4b 
and the four respective Mg-organyls of 5-8, are presented in Scheme 2.12 and Table 
2.3: 
 
Scheme 2.12 
Table 2.3: Nucleophilic ring-opening of aziridines by various aryl cuprates 
Entry Aziridine ArBr Product Yield (%) By-productsb 
1 4a 5 9a 60 PhCH2OH 
2 4b 5 9b 81 13 
3 4a 6 10a 45 PhCH2OH 
4 4b 6 10b 49 13 
5 4a 7 11a 51 PhCH2OH 
6 4b 7 11b 40a 13 
7 4a 8 12a 6 PhCH2OH 
8 4b 8 12b - 13 
 a) Isolated in a mixture with non-reacted aziridine 4b. 
 b) Biaryls (Ar-Ar) were detected in all reactions. 
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The synthesis of various analogues required typically at least 2 equivalents of the 
respective Grignard-reagent to reach acceptable yields. Attempts with 1.0-1.5 
equivalents of the nucleophile resulted in very low yields, and even failed to provide 
any product in some cases. In gram scale experiments, we found it necessary to add up 
to 3 equivalents of the aryl Grignard reagent due to significantly lower conversion. This 
was most probably due to factors like time and volume, resulting in a larger degree of 
decomposition of the Grignard-reagents. Compounds 9a and 9b were typically isolated 
in 60-80% yield, and represent the most successful ring-opening reactions. The 
fluorinated analogues 10a and 10b were more problematic, first of all due to lower 
conversion. Isolation of these two products 10a and 10b resulted typically in 45-50% 
yield. The ortho-analogues 11a and 11b were also challenging with respect to 
conversion, and were isolated in 40-50% yield. Reactions with the highly electron rich 
veratrole nucleophile, prepared from 4-bromoveratrole (8), proved to be very 
challenging. While a small amount of the product 12a was isolated and characterised in 
6% yield, no product 12b was detected. In the ring-opening reactions of aziridine 4b 
(entries 2, 4, 6 and 8), various amounts (4-27% yield) of N-Ts-alkene 13 were isolated 
as by-products, formed by base catalysed isomerisation (Scheme 2.13). Such base-
promoted isomerisation reactions are well known from epoxides,116 while for aziridines 
the literature is more limited.117,118  However, a mechanism involving aziridinyl anions 
followed by a 1,2-H shift (chemistry recently reviewed by Florio and Luisi119) can not 
be excluded.  
 
 
Scheme 2.13 
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Isolation of the ring opening products by flash chromatography turned out to be difficult 
in several cases, especially for the product 11b, since unreacted aziridine 4b tended to 
eluate very similarly. In the case of the product 10b, a complete separation from alkene 
13 was problematic. In all the ring-opening reactions with N-Cbz-aziridine 4a, we 
observed various amounts of benzyl alcohol (up to 23% yield) in the crude reaction 
mixture. This is a typical by-product from the cleavage of Cbz-groups, and underscores 
that such protection groups are not compatible with hard organo-magnesium-
reagents,94d unless very mild reaction conditions are provided. Other significant by-
products were the respective biaryls (Ar-Ar), known as Wurtz coupling products, which 
appear especially with electron rich aryls.120        
 
As a conclusion, our results revealed that the three copper anisole substrates, derived 
from arylbromides 5-7, ring-opened aziridines 4a and 4b regioselectively. An obvious 
drawback was the conversion, providing typically moderate yields. Based on this, we 
are confident that with some more effort on optimisation, the yields might be improved. 
On the other hand, synthesis of the products 12a/12b obviously requires completely 
different reaction conditions in order to succeed.  
 
Motivated by that, we decided to investigate other possibilities to synthesise these 
veratrole derivatives. Turning our attention to Lewis acid catalysis, we decided to test 
the possible Friedel-Crafts type coupling between N-Ts-aziridine 4b and veratrole 14. 
An attempt with N-Cbz-aziridine 4a was not even considered, because of the N-
carboxyaziridines urge to rearrange to oxazolines under Lewis acid catalysis.121    
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Scheme 2.14 
Two classical azaphilic Lewis acids, Cu(II)triflate122 and BF3-etherate,123 were tested 
and found to be unsuccessful for the envisioned reaction (Scheme 2.14). Both attempts 
provided lactone 15 as the main product, which was identified and characterised 
according to literature published by Bergmeier and co-workers.124   Mechanistically, 
this is comparable to related N-Ts-aziridines (substituted with a -ester function) which 
are reported to undergo base catalysed reactions to provide five membered lactone 
rings.118 Successful ring-opening reactions by aryl systems are indeed found in the 
literature, but such N-Ts-aziridines are attached to -phenyl moieties, capable of 
benzylic stabilisation of intermediate carbocations.125,126 As a consequence, it appears 
that Lewis acid catalysed intermolecular ring opening reactions of N-Ts-aziridine 4b 
with a -carbonyl group, are suppressed by a rapid intramolecular cyclisation.  
 
Alternative methods to synthesise veratrole derivatives 12a and 12b were not attempted, 
thereby deciding to surrender (S)-2-amino-6,7-dimethoxytetralin as a target molecule.       
 
2.3.5 Deprotection of tert-butyl esters 
A selective cleavage of the tert-butyl protective group in coupling products 9a-b, 10a-b, 
and 11a-b, were required prior to cyclisation. This was performed according to the 
procedure published by Mehta and co-workers, in which acidolysis is performed with 
trifluoroacetic acid in DCM.127 The improvement in this methodology compared with 
the classical approach can be subscribed to the addition of triethylsilane, which works 
  
Chapter 2 – Chiral pool synthesis of 2-aminotetralins – Part I 
 
29 
as a carbocation scavenger. As a consequence, shorter reaction times and improved 
yields have been obtained. This method yields only volatile by-products and requires no 
aqueous work-up. Scheme 2.15 and Table 2.4 summarises the results obtained for the 
tert-butyl deprotection reactions.  
 
Scheme 2.15 
Table 2.4: Deprotection of tert-butyl esters by acidolysis 
Entry t-Bu ester Acid Yield (%) 
1 9a 16a 78 
2 9b 16b 89 
3 10a 17a 12a 
4 10b 17b 84 
5 11a 18a 68 
6 11b 18b 52b 
  a) Unexpected problems during work-up. Decomposition of product. 
  b) Isolated as a mixture with N-Ts-lactone 15.  
 
After some initial testing, we decided to implement column chromatography as a final 
purification step to obtain pure acids, despite the fact that the expected by-products are 
volatile.127 The ester cleavage gave moderate to good yields, with one exception. The 
crude reaction mixture of 17a, indicated a high degree of conversion, but appeared as a 
rather complex crude mixture. Initial purification attempts by recrystallisation from 
diethyl ether/n-pentane failed. Later, by the aid of semi-gradient column 
chromatography, some pure material was isolated. However, the amount was not 
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sufficient to attempt cyclisation of acid 17a. Another observation was the 
transformation of N-Ts-aziridine 4b, from the impure starting material of 11b, to N-Ts-
lactone 15. This is basically the same reaction as described in Scheme 2.14, but in this 
case catalysed by a Brønsted acid instead of a Lewis acid.    
2.3.6 Intramolecular cyclisation to tetralone frameworks 
To construct the desired tetralone framework, acids 16a-b, 17b and 18a-b had to be 
cyclised. To achieve that, we turned our attention to classical Friedel-Crafts (F-C) 
acylation reactions. Initially, a reagent for the preparation of the intermediate acid 
chloride was required. For this reaction, three well known reagents were considered, i.e. 
thionyl chloride (SOCl2), oxalyl chloride ((COCl)2) and phosphorous pentachloride 
(PCl5). Initial test reactions were performed with substrates 16a and 16b, and it soon 
became evident that heating in thionyl chloride was not worthwhile, resulting in a 
gradually black coloured reaction mixture. Any attempts to isolate products or efforts to 
find an explanation for this destructive finding was not performed. Turning our attention 
to oxalyl chloride and PCl5, we found that both were able to make the acid chlorides. In 
order to identify an optimal Lewis acid for the attempted cyclisation, several candidates 
were tested, i.e. aluminium(III)chloride (AlCl3), tin(IV)chloride (SnCl4), boron 
trifluoride etherate (BF3.Et2O) and  trimethylsilyl triflate (TMSOTf). After a series of 
initial approaches, we found that both, AlCl3 and SnCl4, were suitable for performing 
the cyclisation reaction. We decided to use the latter because of the practical volumetric 
addition. The PCl5/SnCl4-combination has also been used in several other reactions, 
with related substrates.88,128-131 The reactions were typically run at 0 ºC or at room 
temperature.  
As an alternative approach, the cyclisations were also performed using a protocol 
described by Gonnot and co-workers, utilising a mixed anhydride made from a 
TFAA/TFA-mixture in DCM.132 At room temperature, an electron rich aryl 
intermediate was reported to provide a high yield within 15 min. An interesting 
observation is the fact that cyclisation occurs meta to the activating methoxy group, 
thereby suggesting that the activation is less crucial in this very reactive system. The 
results of our cyclisation attempts are described in Scheme 2.16, Table 2.5. 
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Scheme 2.16             
Table 2.5: Cyclisation reactions of acid 16a-b and 17b 
Entry Acid Meth. Conditions I : IIa Product % Yield 
1 16a A 0 ºC (0.5 h)  rt (3 h) 97 : 3 19a 25 
2 16a A 0 ºC, 4 h 97 : 3 19a 28 
3 16b A 0 ºC (1 h)  rt (3 h) 95 : 5 19b 27b 
4 16b A 0 ºC, 6 h 91 : 9 19b 40 
5 16b B rt, 0.5 h 78 : 22 19b 23 
6 16b B rt, 16 h 78 : 22 19b 9 
7 17b A 0 ºC (1 h)  rt (3 h) 100 : 0 20b 39c 
8 17b A 0 ºC, 4 h 100 : 0 20b 41 
9 17b B 0 ºC, 4 h 100 : 0 20b 29 
    a) Indicates the ratio between Pathway I and II, estimated by 1H NMR-analyses. 
    b) 22 (30% yield) and 24 (3% yield).   
    c) 23 (30% yield). 
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Focusing on the F-C acylation reactions of N-tosylated acids 16b and 17b (Method A), 
cyclisation of 16b at room temperature (entry 3) resulted in significant amounts of 
naphthalenes 22 and 24. Both of these compounds have been described in the 
literature.133,134  From the same reaction mixture, para-toluenesulfonamide (p-TsNH2) 
was also isolated. We rationalised these findings to result from an aromatisation of the 
products from the Pathway I and II cyclisations. Interestingly, we were not able to 
isolate the cyclisation product from Pathway II (Scheme 2.16). However, we observed 
that the total amount of the products 19b and 22, compared to the amount of product 24, 
remained at a constant ratio during the reaction process. We therefore decided to use 
this as a value for the ratio between the respective reaction pathways. A possible 
explanation for these findings can be attributed the respective tetralone’s keto-enol 
tautomerism. While product 19b is most stable in the keto-form, as most ketones are, 
the Pathway II cyclisation product has a stabilised enol-form due to hydrogen bonding. 
This enol is the structure that causes a favourable aromatisation releasing naphthalenes 
(Scheme 2.17). 
 
 
Scheme 2.17      
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Lowering the temperature from room temperature to 0 ºC improved the yield of 19b 
from 27% to 40% (entries 3 and 4), but the regioselectivity was slightly lowered. The 
formation of the fluorinated analogue 20b was entirely regioselective, and no Pathway 
II cyclisation product was observed. By-product 23 (Scheme 2.16) was isolated and 
characterised as a new monofluorinated naphthalene derivative. Running the reaction at 
0 ºC instead of room temperature, improved the yield from 39% to 41% (entries 7 and 
8). Comparison with the results of the alternative method B (entries 5, 6 and 8), show 
that the yields obtained were in the same range. Regarding the regioselectivity, it 
decreased in the case of 19b, while 20b still yields only the para products. Finally, we 
observed that N-Cbz acid 16a reacted slightly more regioselectively than the N-Ts 
substituted analogue 16b. The amount of by-products 22 and 24 were also significantly 
lower. However, the isolated yield was also in this case quite low (entries 1 and 2).    
 
Cyclisation of 18a and 18b was in principle expected to occur meta to the methoxy 
group, producing only one product. However, attempts with both methods failed to give 
any sufficient amounts of product 21a (Scheme 2.18).   
 
 
Scheme 2.18 
 
As a conclusion, we did not reach higher than 41% yield in any of these attempts, which 
was rather discouraging. A main reason may be the somewhat surprising aromatisation 
reactions of 19b and 20b. In the case of N-Cbz acid 16a, the amount of by-products 
indicate the occurrence of alternative reaction pathways.     
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In two recent publications, a combination of indium(III)bromide and 
dimethylchlorosilane was utilised as F-C acylation reagents.135,136 Successful 
transformations were reported starting from the free acid, as well as various esters like 
tert-butyl-, benzyl- and isopropyl. The basis for these reactions was the observation that 
dimethylchlorosilane reacted with the acid (or ester) at the expense of it’s silane proton, 
forming a chlorosilyl ester. This chlorosilylester was found to mimic an acid chloride in 
a F-C reaction, and through In(III)bromide catalysis, acylation reactions occurred. In a 
series of various reactions, both intra- and intermolecular, yields were reported to be 
good to mediocre. We decided to investigate this protocol and performed reactions with 
both acid 16b and ester 9b. However, both attempts failed to give tetralone 19b at 80 
ºC, according to the protocol. Decreasing the reaction temperature to 50 ºC resulted in a 
gradually decomposition of the starting material. Based on this, we decided to avoid this 
alternative “high” temperature approach, since the tetralone intermediates 16a-b and 
17b had already proven to aromatise at relatively low temperatures (Scheme 2.16).     
 
2.3.7 Deoxygenation of N-Ts tetralones 
Deoxygenation of tetralones 19b and 20b were found to proceed well by medium 
pressure catalytic hydrogenation over Pd/C, in a modified literature procedure (Scheme 
2.19).89  
 
 
Scheme 2.19 
Tetralins 25b and 26b were isolated in 57% and 76% yield, respectively. HPLC-
analysis using a chiral column was performed for product 25b, verified a high 
enantiopurity (99% ee). 
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2.3.8 One-pot deoxygenation and deprotection of N-Cbz-tetralone 
Tetralone 19a was deoxygenated and deprotected by a one-pot catalytic hydrogenation 
reaction over Pd/C (Scheme 2.20).  
 
H
N
Cbz
H3CO
O
NH3H3CO
i) H2 (5 atm)
Pd/C
ii) concd HCl
AcOH
rt
19a 27-HCl
Cl
 
Scheme 2.20 
 
The liberated (S)-2-amino-7-methoxytetralin (27) was transformed into an easy to 
handle HCl-salt 27-HCl in 70% yield. Analysis showed consistency with the literature, 
without any significant signs of racemisation (99% ee).91 (HPLC analysis on a chiral 
column performed after a derivatisation of 27-HCl to tosylate 25b.)   
 
2.3.9 Deprotection of N-tosyl groups 
Traditionally, rather harsh conditions are necessary to cleave tosyl groups from the 
amines. Typical one-electron transfer reagents like lithium or sodium have been utilised, 
which in many cases are not compatible with various functional groups. The same 
problem also arises when hydrolysis under very strong acid conditions (e.g. HBr, 
HClO4) is attempted. More selective and sophisticated techniques utilising 
photoreactions, electrolysis or various metal reagents for the deprotection are known, 
but they tend to be non-general methods.94e In a very recent publication by Ankner and 
Hilmersson, an instantaneous and mild deprotection method was described.137 In a 
combination of water and pyrrolidine (or other aliphatic amines), samarium diiodide is 
capable to cleave the protective group elegantly at room temperature. Scheme 2.21 
describes our attempts to perform the deprotection according to this protocol. 
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Scheme 2.21 
 
Deprotection with SmI2 proved to be both simple and extremely rapid. The isolated 
yields of 27-HCl and 28-HCl were 45% and 65%, respectively. The reason for these 
moderate yields can partly be attributed to the quality of the reagent, but also problems 
related to inaccuracy in small scale syntheses may not be excluded. Analysis of the 
optical purity also confirmed that no significant racemisation occurred.26,91  
 
Another N-tosyl deprotection method is presented in chapter 4.3.7, where tetralone 27 
was isolated in 82% yield from N-tosylamine 25b. In this method, a trifluoroacetyl 
group adds to form a bis protected amine prior to the addition of SmI2. After this 
detosylating step, basic hydrolysis cleaves the trifluoroacetyl-group and liberates the 
free amine 27 (see chapter 4.3.7 for details).      
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2.4 Summary 
Aspartic acid 4-tert-butyl ester (1) was chosen as our starting material and three 
alternative N-protecting groups (Cbz, Ts and Boc) were evaluated. We were able to 
synthesise two out of four target molecules (27-HCl and 28-HCl) by the developed 
methodology. Scheme 2.22 illustrates the synthesis of 27-HCl, utilising Cbz as the N-
protecting group, which provided the best result totally.   
 
    
Scheme 2.22 
 
Reduction to the corresponding amino alcohols (3a-c) proved to be quite 
straightforward for carbamates 2a and 2c, but failed to reduce tosylate 2b to N-Ts amino 
alcohol 3b. To circumvent this, a transformation of 3a to 3b became the method of 
choice. Aziridinations of amino alcohols 3a-c were synthesised utilising Mitsunobu 
conditions. Ring opening reactions with four bromoanisole derivatives worked 
satisfactory for three of them (2-bromoanisole, 3-bromoanisole and 5-bromo-2-
fluoroanisole), while 4-bromoveratrole failed to produce any significant amounts of 
ring-opening products 12a and 12b. Hydrolyses of the tert-butyl esters resulted in good 
to moderate yields, with one exception (12% yield for 17a). The most challenging step 
proved to be the cyclisations to the tetralone moiety. A typical Friedel-Crafts acylation 
and a mixed anhydride protocol were both tested, but we were not able to rise above 
41% yield in any attempt. One of the main problems was the ability of the produced N-
Ts tetralones (19b, 20b) to aromatise into naphthalenes while eliminating TsNH2. The 
stability of the Cbz protecting group also caused a problem in the synthesis of N-Cbz 
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tetralone 19a. Deoxygenation and deprotection of 19a to target molecule 27-HCl was a 
straightforward reaction, while 19b and 20b required a two step deoxygenation and 
deprotection procedure.              
    
As a conclusion, we have developed a new total synthesis for substituted (S)-2-
aminotetralins, where the key step is the fusion of the two synthons through a ring 
opening reaction of an aziridine with an appropriate nucleophile. With the exception of 
a problematic cyclisation step (41% yield and lower), the other steps provided decent 
yields. However, it was found that tosyl- and Cbz-protection of the amino group are not 
adequate for this total synthesis. If this synthesis should find a general application at a 
later stage, other protection groups must be evaluated. To broaden the amount of 
potential analogues, a larger effort in the optimisation of ring opening reactions of the 
aziridines has to be conducted, especially in the utilisation of very electron rich aromatic 
compounds (e.g. dimethoxybenzene). Limitations to very sterically demanding 
substrates might also be a factor to consider if one decides to attempt the synthesis of 2-
aminotetralins with relatively large substituents.        
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2.5 Experimental 
The full experimental description for Chapter 2 is reported in Paper I. Two exceptions 
which are not included in this paper are the experimental procedures and the data for 
compounds 4c and 49, which are provided below. 
 
(S)-tert-Butyl 2-(2-tert-butoxy-2-oxoethyl)-aziridine-1-carboxylate (4c). 
 
 
Commercially available N-Boc-L-aspartic acid (2c) was reduced to the corresponding 
N-Boc-amino alcohol 3c according to the procedure by Rodriguez and co-workers,96 in 
78% yield. The data for 3c was compatible with the reported values from Hamprecht 
and co-workers.138 
 
Alcohol 3c (1.01 g, 3.66 mmol) and triphenylphospine (1.92 g, 2 equiv) were dissolved 
in dry THF (10 ml) and cooled to 0 °C. After addition of DEAD (1.14 ml, 2 equiv), the 
mixture was allowed to reach room temperature, and reacted further for 2h. The crude 
mixture was concentrated to approx 2 ml, before it was transferred to the 
chromatography column. Elution with 15% EtOAc in n-hexane provided 438 mg of 4c 
(46% yield). Data for 4c: Rf = 0.49 (15 % EtOAc in n-hexane).  rtD  +70.5 (c 0.2, 
CH2Cl2). 1H NMR  (400 MHz):  2.74-2.67 (m, 1H, CH-N), 2.62 (dd, J=15.8, 5.8 Hz, 
1H, CHHC=O), 2,32 (d, J=6.0 Hz, 1H, CHH-N), 2.21 (dd, J=15.8, 7.0 Hz, 1H, 
CHHC=O), 1,99 (d, J=3.6 Hz, 1H, CHH-N), 1.47 (s, 9H, tBu), 1.46 (s, 9H, tBu). 13C 
NMR (100 MHz):  169.8 (RC(=O)O), 162.1 (OC(=O)N), 81.3 (tBu), 81.1 (tBu), 38.8 
(CH2C=O), 33.8 (CH-N), 31.3 (CH2-N), 28.1 (tBu), 28.0 (tBu). IR (thin film, NaCl): 
2979 (w), 1724 (m), 1394 (m), 1305 (m), 1257 (m), 1225 (m), 1154 (s), 854 (m) cm-1. 
HRMS (ESI) calcd for C13H23NO4Na (M+Na)+ 280.1519, found 280.1530. 
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 (S)-tert-Butyl 2-(2-oxooxazolidin-4-yl)acetate (49).  
 
HN
O
O
COOtBu
49  
Tosylation of N-Boc-alcohol 3c was performed according to a literature procedure in 
90% yield, and compatible data for tosylate 3c-Ts were observed.102 Tosylate 3c-Ts 
served as the starting material in the synthesis of oxazolinone 49, which was performed 
according to reaction conditions provided by a literature procedure.139     
 
Tosylate 3c-Ts (20 mg, 0,046 mmol) was dissolved in dioxane (1.0 ml) and added 
2,4,6-trimethylpyridine (15 l, 0.1 mmol) and LiClO4 (49 mg, 0.46 mmol). The reaction 
mixture was heated to 70 ºC for 3 hours. At room temperature, the mixture was 
partitioned between EtOAc (10 ml) and 10% citric acid (10 ml). The aqueous layer was 
extracted with additional EtOAc (2 x 10 ml), and the combined organic fractions were 
dried (MgSO4) and concentrated. Compound 49 was isolated as a colorless oil (7 mg, 
74%). Data for 49: Rf = 0.17 (40% EtOAc in n-hexane). 1H NMR  (400 MHz):  5.5 (bs, 
1H, NH), 4.54 (dd, J=8.8, 8.3 Hz, CHHO), 4.23-4.11 (m, 1H, CH), 4.04 (dd, J=8.80, 
6.00 Hz, 1H, CHHO), 2.59 (dd, J=16.8, 8.0 Hz, 1H, H-2), 2.52 (dd, J=16.8, 5.6 Hz, 1H, 
H-2), 1.46 (s, 9H, CH3). 13C NMR (100 MHz):  169.8 (C-1), 158.7 (NC(=O)O), 82.2 
(C(CH3)3), 69.3 (CH2O), 48.9 (CH), 40.7 (C-2), 28.1 (CH3).  
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3 Chiral pool synthesis of 2-aminotetralins - Part II 
3.1 Background 
Based on the results described in Chapter 2, an alternative approach starting from L-
aspartic acid was also evaluated. First of all, we decided to simplify the procedure by 
avoiding the selective -esterification. Second, we wanted to make an aziridine 
precursor capable of performing the ring-closing reaction (aziridination) without the use 
of Mitsunobu-conditions (i.e. avoiding azo-reagents). And third, we had a strong urge to 
improve the troublesome tetralin cyclisation, and wished to test a different substrate 
with more suitable protection groups.  
 
3.2 Retrosynthesis 
In this attempt, L-aspartic acid is N-protected and reduced to a diol (e). The aziridine f 
can then be obtained through a double tosylation of the free OH-groups of the diol e. 
Regioselective ring opening of the aziridine f by an aryl nucleophile (g) should then 
provide the ring-opened product (h). Final cyclisation may then be performed to the 
desired 2-aminotetralin. (Scheme 3.1): 
 
 
Scheme 3.1 
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3.3 Results and discussion 
The total synthesis presented here in chapter 3 aims to be a general route towards 
enantiopure 2-aminotetralins, with various aryl substituents. In the development and 
evaluation of the stepwise process, however, only (S)-2-amino-7-methoxytetralin (27) 
was chosen as target molecule.    
3.3.1 Preparation of N-Boc protected diol 
Aspartic acid was esterified in methanol in the presence of thionyl chloride, by the 
procedure of Gmeiner and co-workers (Scheme 3.2).140 A simple work-up was 
sufficient to yield the relatively pure amino acid ester 31 as a hydrochloride salt. 
Subsequent protection of the amine function was performed by the introduction of a 
Boc-group, yielding N-Boc-ester 32 in 92% yield. The procedure was based on a patent 
description, for the protection of an analogue diethyl ester.141  After a work-up with 
careful pH-control, pure crystalline product 32 was isolated. Reduction was performed 
with NaBH4 in refluxing ethanol.141 After a rather tedious work-up, including several 
extractions, diol 33 was isolated in 89% yield (Scheme 3.2). 
  
COOHH2N
COOH
SOCl2
MeOH
rt
93% yield31
COOCH3H3N
COOCH3
Cl
L-Aspartic acid 32
COOCH3
H
N
COOCH3
Boc(Boc)2O
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Dioxane
92% yield
33
H
N
Boc OH
OH
NaBH4 abs. EtOH
ref lux
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Scheme 3.2 
  
Chapter 3 – Chiral pool synthesis of 2-aminotetralins- Part II  
 
43 
3.3.2 Ring-closing reaction to aziridine 
Keeping our experiences from chapter 2.3.3 in mind, we did not believe that tosylation 
and aziridination of N-Boc-diol 33 was the right approach because of the expected 
oxazolinone formation. However after discovering a successful cyclisation reaction 
presented by Wessig and Schwartz,142 we decided to pursue this strategy. In this 
protocol, excess pTsCl and powdered KOH react in boiling diethyl ether with N-Boc--
amino alcohols, forming the respective aziridines. After some testing we were able to 
synthesise N-Boc-aziridine 34 in 76% yield (Scheme 3.3).  
 
 
 Scheme 3.3 
 
Based on our previous experiences, and now from the successful aziridination of 33 
(and more supporting literature143-146), it appears that strong basic (i.a. KOH, NaH, 
LiHMDS, Et3N) conditions for tosylated (or mesylated) N-acyl (or N-carbamoyl)--
amino alcohols may have two distinct outcomes, i.e. aziridination or oxazolinone 
formation. However, we were not able to predict the preferred outcome for these 
reactions, concluding that the reactions are strongly substrate dependent.   
 
This result also demonstrates quite clearly that substrate 33 has a strong preference to 
undergo cyclisation to our target molecule, a three membered aziridine ring (34), rather 
than a potential four membered azetidine ring (Scheme 3.4). This can be explained by 
the conformations of 33-Ts responsible for the respective cyclisations, where 34 is 
formed through the more favourable staggered conformation. In terms of entropy factor, 
attack on the -position is strongly favoured, with a reaction rate about 100 times higher 
than a -position attack.147 Nevertheless, in a related example with a very sterically 
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demanding N-protective group (Pf), a preference for azetidine formation on the expense 
of aziridine formation, has been demonstrated.139    
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Scheme 3.4 
In conclusion, this method seems to work surprisingly well and reaction mixtures do not 
indicate any significant by-product besides various amounts of unreacted 33-Ts. 
Another positive consequence of this method was the remaining tosyl group, which 
could serve as a protection group in the next step (see chapter 3.3.3). 
 
3.3.3 Ring-opening reaction by aryl nucleophiles 
By using the same methodology as described in chapter 2.3.4, we were able to 
successfully ring-open aziridine 34 with the aryl nucleophile made from 3-bromoanisole 
(5) (Scheme 3.5). The reaction required at least 2 equivalents of the Grignard-reagent to 
achieve high conversion and yield.  
 
Scheme 3.5 
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It soon became evident that the compound was somewhat unstable. Stability tests 
performed revealed that 50% of the product had decomposed after 6 hours in boiling 
THF, and 23% decomposed in boiling DCM within the same time. As a consequence, 
drying of the purified product 35 was performed at room temperature (high vacuum) 
before storage at low temperature (-18 ºC).  
 
To synthesise target molecule (S)-7-methoxy-2-aminotetralin (27) from tosylate 35, two 
alternative approaches were tested. The results of the intramolecular Friedel-Crafts 
alkylations are summarised in the following chapter, while the results from the 
cyclodehydration strategy are presented in chapter 3.3.5.       
 
3.3.4 Intramolecular Friedel-Crafts alkylation   
A standard procedure for a Friedel-Crafts (F-C) reaction typically utilises an acyl- or 
alkyl halide, with an appropriate Lewis acid. Generally, F-C acylations work better than 
the alkylations, which require tougher reaction conditions and may give additional 
alkylations due to increased ring activation.148 Little is known about the possibilities for 
intramolecular F–C alkylations of alkyl tosylates, or other sulfone based (e.g. mesyl, 
triflate) leaving groups. 
 
To pursue this possibility, an initial test reaction with tosylate 35 was performed under 
F-C conditions (Scheme 3.6). Early observations revealed, however, that cleavage of the 
Boc-group occurred rapidly even at room temperature. To circumvent this problem, a 
replacement of the Boc-group by a more Lewis acid stable protecting group seemed to 
be essential. To achieve this, a trifluoroacetyl group was introduced to double protect 
the amine function. This choice was based on the results presented in Scheme 2.2, 
demonstrating the Lewis acid compatibility of trifluoroacetylamines. Another factor 
was the simple introduction and deprotection protocols for this group.94g Scheme 3.6 
demonstrates the introduction of the trifluoroacetyl group to the double protected amine 
36. 
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Scheme 3.6       
Attempts to perform a intramolecular F-C type cyclisation of tosylate 36 was, however, 
unsuccessful with titanium(IV) chloride (80 °C, DCE). Analysis of the main product 
revealed that not only was the Boc group cleaved off, the tosyl group was exchanged by 
a chloride as well (see Scheme 3.7).  
 
 
Scheme 3.7 
A similar observation from the literature supports this substitution, when a oxophilic 
Lewis acid like titanium(IV) chloride was used in a reaction with an alkyl tosylate.149 
Through the newly formed alkyl chloride 37, we now had synthesised a substrate 
suitable for classical F-C alkylation reaction.  
 
 
Scheme 3.8 
For comparison to the chloride 37, we also decided to synthesise the corresponding 
iodide from tosylate 36. The main reason for this was to broaden the possibilities of 
combining both hard and soft alkyl halides with various Lewis acids. Iodide 38 was 
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prepared through a typical substitution reaction protocol with sodium iodide in acetone 
(35 °C), in 78% yield (Scheme 3.8).150  
 
The results from the cyclisation reactions of chloride 37 and iodide 38 are summarised 
in Scheme 3.9 and Table 3.1:   
 
 
Scheme 3.9 
Table 3.1: Cyclisation of chloride 37 and iodide 38 under various reaction conditions 
Entry Substrate Solvent Lewis 
acid 
 
Temp 
(ºC) 
Time 
(h) 
Ratiob 
39 : 40 
39 
% yieldc 
(% ee)d 
1 37 DCE AlCl3 
(2 equiv) 
80  7  - -e 
2 37 DCE AlCl3 
(2 equiv) 
reflux 20  - -e 
3 37 DCE InBr3 
(2 equiv) 
reflux 20  69 : 31 complex 
mixture 
4 37 DCM  AlCl3 
(3 equiv) 
100a 20  83 : 17 36% 
(99% ee) 
5 37 DCM InBr3 
(2 equiv) 
80a 20  68 : 32 <15% 
(99% ee) 
6 37 DCM SnCl4 
(3 equiv) 
80a 20  - -e 
7 37 DCM BF3.Et2O 
(3 equiv) 
80a 20  - -e 
8 38 DCM InBr3 
(2 equiv) 
80a 18  71 : 29 26% 
(97% ee) 
a) Reaction performed in closed pressure tube. 
b) Ratio determined according to 1H NMR spectrum of the product mixture. 
c) Isolated yield after purification. 
d) The enantiomeric excess of the products was determined by HPLC. 
e) No reaction.  
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The results from the reactions in Table 3.1 demonstrate that both, chloride 37 and iodide 
38, can be cyclised into our target molecule 39, but the reactions were not entirely 
regioselective, i.e. significant amounts of ortho product 40 was formed as well. A 
comparison of entry 4 with entries 3, 5 and 8, indicates that aluminium(III) chloride 
gives a significantly better regioselectivity than indium(III) bromide, even at a higher 
reaction temperature. Isolated yields are moderate to low in these initial attempts, but if 
some optimisation effort can be performed, more decent yields should be within reach. 
Products 39 and 40 were only partly separable by column chromatography, so improved 
chromatographic conditions are also required. Analyses of the enantiomeric excess 
revealed that the racemisation does not represent any problem in the total syntheses 
from enantiopure L-Aspartic acid.   
 
Our target molecule (S)-7-methoxy-2-aminotetralin (27) is accessible through basic 
hydrolysis of trifluoroacetyl amine 39, following a procedure (K2CO3, MeOH/H2O, rt) 
described by Gómez-Sánches and co-workers, in up to quantitative yields.151            
 
3.3.5 Phthalimide protection and cyclodehydration reaction 
An alternative to the intramolecular Friedel-Crafts alkylation strategy is the 
cyclodehydration of the corresponding alcohol. Since the mid thirties, acid catalysed 
cyclodehydration of 4-phenylbutanols to their corresponding tetralins have been 
known.152,153 More recently, methods utilising stoichiometric amounts of triflic acid or 
phosphoric acid have successfully been implemented in cyclodehydrations of electron 
rich arenes.154,155 Inspired by the work published by Harris and co-workers,154 we 
decided to investigate if tosylate 35, after a transformation to the acid stable phthalimide 
44,94h would cyclise correspondingly (Scheme 3.10). Based on this, we aimed to 
synthesise the phthalimide protected target molecule 44, which is a structural isomer of 
the one published by Harris and co-workers.            
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Scheme 3.10 
 
Since compound 35 is prone to react rapidly with nucleophiles in tosylate substitution 
reactions, we found it necessary to replace tosyl by a hydroxyl group. Early test 
reactions with excess KOH indicated that the cleavage was quite efficient, but it was 
accompanied by the loss of the Boc protection group. Analyses revealed that under 
these conditions, carbamate 42 was formed. A plausible mechanism for this elimination 
and cyclisation process is shown in Scheme 3.11.    
 
Scheme 3.11 
Two sets of reaction conditions were found to execute the synthesis of cyclic carbamate 
42 efficiently, i.e. in DMSO at room temperature and in aqueous dioxane at 50 ºC. The 
prior conditions provided a yield up to 60%.  
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An alternative for the tosyl-cleavage with hydroxide nucleophiles is the application of 
samarium(II)iodide in a one electron transfer mechanism.137 This method is applicable 
to both O-Ts and N-Ts groups, as already demonstrated in section 2.3.9. Based on this, 
we tested the conditions for compound 35 (Scheme 3.12).   
 
Scheme 3.12 
 
It early became evident that this reaction system was not very efficient. Even with six 
equivalents of SmI2, the turnover was still moderate and provided several products. One 
possible explanation is the lack of stability of the reagent. While the SmI2-reagent was 
freshly prepared (samarium, diiodoethane, THF, rt, 1h) before the reaction in the above 
mentioned literature, only premade solutions from a chemical supplier were tested in 
our case. In a specific test with a newly opened bottle of SmI2 in THF, we were only 
able to isolate 41 in 32% yield. Based on this, and the fact that this reagent is relatively 
expensive, this pathway was discarded.    
 
Through different N-Boc deprotection reactions of compounds 41 (HCl, toluene, 65 °C) 
and 42 (LiOH, MeOH/H2O, 70 °C then HCl-treatment), we were now able to synthesise 
amine 43 as an HCl-salt (Scheme 3.13). 
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   Scheme 3.13 
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The cyclic carbamate 42 was opened by lithium hydroxide hydrolysis, using a modified 
procedure published by Curtis and co-workers in 65% yield.156 Liberation of the N-Boc 
protection group in carbamate 41 was performed by treatment with hydrochloric acid in 
toluene at 65 °C, giving 80% yield.157 Through these two alternative pathways, amine 
43 was now accessible for protection to the double N-protected and acid stable 
phthalimide compound 44 (Scheme 3.14).   
 
 
Scheme 3.14 
 
The reaction was performed with freshly prepared phthalic anhydride (double 
recrystallised from CHCl3 and dried) and dry toluene.158 Despite of that, we only 
achieved 43% yield of 44 after several attempts. A probable reason for the moderate 
yield can be ascribed to the fact that we did not utilise a Dean-Stark apparatus, which 
would efficiently remove the produced water and thereby shift the reaction towards the 
product 44. For larger scale reactions (here approx 100 mg 43) and with the above 
mentioned equipment, we expect this reaction to proceed in potentially higher yields.   
 
The target molecule 44 was tested under the reaction conditions (F3CSO3H, PhCl, 80 
°C, 4h) for cyclodehydration, as described by Harris and co-workers154 (Scheme 3.8). 
The reaction provided several products, but the two main products 45 and 46 were 
isolated and investigated closer. After initial 1H and 13C NMR analyses, we observed 
that for both products, the phthalimide ring system was not intact. Both structures gave 
rise to six non-equivalent aromatic carbon atoms and only one carbonyl signal. Through 
these observations, a reaction involving the phthalimide group was suggested. After 
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more thorough analyses, we now believe that Scheme 3.15 describes the outcome of this 
reaction. 
 
 
      Scheme 3.15 
 
Compound 45 (absolute configuration determined by NOESY experiments) results from 
the initial reaction with the phthalimide group. Product 46 is the result of an additional 
dehydration step with the intramolecular formation of an ether linkage, forming a 
favourable six membered ring.     
 
Compounds 45 and 46 can be classified as isoindolo[1,2-a]isoquinolinone derivatives, 
related to the natural product (±)-nuevamine (Figure 3.2), isolated from Berberis 
darwinii Hook species.159 This isoquinoline alkaloid is still considered as the only 
representative of this family, nevertheless, several general approaches to synthesise 
isoindolo[1,2-a]isoquinolinones (general structure, see Figure 3.1) have emerged in 
literature.160-163 This might be due to the fact that several derivatives are considered to 
have potential biological activities.164   
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Figure 3.1: Structures of (±)-nuevamine and isoindolo[1,2-a]isoquinolinone  
 
Further work with compounds 45 and 46 were not pursued at this stage.   
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3.4 Summary 
Chapter 3 describes the results of a new nine step total synthesis of (S)-7-methoxy-2-
aminotetralin (27) from natural L-aspartic acid (Scheme 3.16).  Several improvements 
have been achieved in this synthetic route compared with the one described in Chapter 
2. The first obvious improvement is the fact that we were able to circumvent the 
selective -carboxylic acid protection of L-aspartic acid. Second, no diazo-reagent 
(DEAD) was required in the ring-closing reaction to the aziridine 34. And third, 
introduction of a trifluoroacetyl amino protecting group in Step 6 resulted in a robust 
and stable substrate able to sustain though Friedel-Crafts conditions. All steps provided 
the products in good to excellent yield with the exception of the intramolecular F-C 
alkylation reactions. Hence, to significantly improve this new route, further efforts in 
the optimisation of this step have to be conducted. With respect to enantiomeric excess, 
no racemisation was observed, yielding 39 in high enantiomeric purity (97 and 99% ee).   
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Scheme 3.16 
In the alternative strategy based on cyclodehydration of the phthalimide protected 
alcohol 44 (Chapter 3.3.5), we were not able to synthesise our target molecule 27. 
Instead we isolated compounds 45 and 46 that are related molecules to the 
isoindolo[1,2-a]isoquinolinone family. No further work, apart from the characterisation 
of these compounds, was performed.       
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3.5 Experimental 
The full experimental description for Chapter 3 is reported in Paper II.  
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4 Asymmetric catalytic aziridination 
4.1 Background 
Aziridination by nitrene addition to alkenes has been known for quite some years.165,166 
Early publications reported that this synthetic approach requires harsh reaction 
conditions, resulting in a total lack of stereoselectivity.167 Since the mid nineties 
however, metal stabilised nitrenes have emerged as useful chiral catalysts in asymmetric 
aziridinations.168 This has greatly extended the methodologies for synthesising 
enantiopure aziridines.     
 
In the following parts of chapter 4.1, a brief introduction to nitrenes and an overview of 
the most commonly used metal-catalysts will be presented. The intention of this is to 
highlight the current knowledge about catalytic systems used in asymmetric 
aziridinations of alkenes.  
 
4.1.1 Nitrenes and nitrene precursors 
Nitrenes are reactive intermediates where nitrogen bears only one substituent, plus 
additional four non-bonded electrons.169 Depending on these non-bonded electrons, they 
can be classified as singlet or triplet nitrenes. In the former and most reactive state, they 
are arranged in two anti-parallel electron pairs. While in the latter and less reactive state, 
one orbital is filled with an anti parallel electron pair and two other orbitals have single 
electrons with a parallel spin. In aziridination reactions of unsymmetrical alkenes, 
singlet and triplet nitrenes react differently. While singlet nitrenes reacts in a concerted 
process, the triplet state reacts in a two step process, with the possibility of free bond 
rotation in the intermediate diradical. As a consequence, singlet nitrene reactions are 
stereospecific, while triplet nitrene react non-stereospecifically (Scheme 4.1).51  
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            Scheme 4.1 
Traditionally, nitrenes have been generated under relatively harsh conditions by thermal 
or photochemical decomposition of azides (Scheme 4.2).  
 
 
Scheme 4.2 
 
In 1975, the synthesis of N-tosyliminoaryliodinane 68 from iodobenzene diacetate 67 
(hypervalent iodine compound) and p-tosylamide 64, was presented as a new type of I-
N ylide (Scheme 4.3).170 The decomposition product of this ylide was found to possess 
an electrophilic character, which reacts with nucleophiles like thioanisole and 
triphenylphosphine. Such reactions are proposed to proceed via a sulfonyl nitrene 
intermediate, thereby defining 68 as a nitrene precursor.     
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Scheme 4.3 
 
These types of compounds have later been found very useful as nitrogen sources in 
asymmetric aziridinations of alkenes, which will be discussed in the following chapters.   
 
4.1.2 Evans and Jacobsen’s copper catalysed aziridinations 
Precursor 68 was the reagent of choice in the copper catalysed aziridination of alkenes, 
published by the group of Evans.171 In their development of this synthetically useful 
method, Cu(I) and Cu(II) salts in acetonitrile were found to be the best catalyst/solvent 
system. The yields obtained, of the various aziridines, were quite substrate dependent 
and varied from low to excellent (23-95%). However, to achieve enantioselective 
nitrene transfer, chiral ligands of the bis(oxazoline) type (see general structure of L*, in 
Scheme 3.4) were later successfully implemented.172 Scheme 4.4 demonstrates a series 
of representative examples utilising this methodology.  
 
Ph
R
N
Ph
R
Ts
O
N N
O
R' R'
TsN IPh
CuOTf , L*
L* =
R' = Ph or tBu
R = COOMe, R' = Ph, 63% yield, 94% ee
R = COOPh, R' = Ph, 64% yield, 97% ee
R = COOtBu, R' = Ph, 60% yield, 96% ee
R = Me, R' = tBu, 62% yield, 70% ee
R = H, R' = tBu, 89% yield, 63% ee
 
Scheme 4.4 
Alternative aryl substituents have also been an object of investigation. Aryl rings 
bearing electron withdrawing (p-nitro, o-nitro, p-trifluoromethyl), electron donating (p-
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methoxy) and sterically demanding (p-tert-butyl) groups have all been synthesised and 
tested as alternatives to compound 68.173    
 
The development of bis(oxazoline) ligands by the Evans group has contributed to the 
development of a range of other bis(oxazoline)-metal complexes, within a broad range 
of applications, which have been summarised in several review articles in recent 
time.174,175  
 
Parallel to the work done by the group of Evans, Jacobsen and co-workers published 
catalytic systems utilising chiral diimine ligands together with nitrene precursor 68 and 
different Cu(I) salts.176,177 After unsuccessful attempts with tetradentate (salen)Cu(II) 
complexes, they realised that bidentate chelation to copper was a requirement. This 
resulted in a series of benzylidene derivatives of 1,2-diaminocyclohexane, capable of 
performing stereospecific aziridinations (Figure 4.1).   
 
 
Figure 4.1 
In a comparison of these two dominant catalytic systems, the Evans bisoxazoline 
ligands are considered as more successful for trans-alkenes, whereas the Jacobsen’s 
diimines are better suited for cis-alkenes.178 Both Cu(I) and Cu(II) metal sources form 
catalysts with the respective ligands, indicating a common oxidation state. Beside this, 
both catalytic systems seem to perform within a quite limited substrate range. 
 
With respect to the mechanism of copper catalysed aziridination with PhI=NTs as 
nitrene source, Jacobsen was the first to suggest a mechanism.177 This mechanism was 
later supported by a mechanistic study by Brandt and co-workers.178 Scheme 4.5 
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demonstrates this general mechanism, where L2 symbolises the respective bidentate 
ligands in Evans and Jacobsen’s catalytic systems.  
 
 
Scheme 4.5 
 
4.1.3 Ruthenium catalysts 
More recently, advances in ruthenium catalysis by Katsuki and co-workers have been 
reported.179,180 Robust Ru(salen)CO complexes have been found useful in asymmetric 
aziridinations, for both ortho- and para-Ns azides as well as for SES (2-
(Trimethylsilyl)ethane sulfonyl) azide. The promising results from the latter azide also 
include the advantage of an easy removable N-protecting group. The examples below 
(Scheme 4.6) highlight two of these results from aziridinations of styrene. 
 
    Scheme 4.6 
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4.1.4 Rhodium catalysts 
Rhodium(II) catalysts have been reported to be quite successful in asymmetric carbene 
transfer reactions, analogue to Cu(I) catalysts.168 Their use in nitrene transfer reactions 
was early investigated, but they were found to be less efficient than the copper catalytic 
systems. However, some chiral Rh-complexes have been reported to give aziridines in 
quite high yields, but unfortunately with low or even no enantioselectivity.181,182 Two of 
these catalysts are presented below (Scheme 4.7), in the aziridination reactions of 
styrene, utilising NsN=IPh as a nitrene precursor.  
 
NsN=IPh
N
Ns
+
Rh-catalyst
Rh2(MEPY)4: 81% yield (21% ee)
Rh2(BEPY)4: 71% yield (27% ee)
Rh
NO
COOMe
N O
MeOOC
N OMeOOC
NO COOMe
Rh
Rh2(5S-MEPY)4
Rh
NO
COOCH2Ph
N O
PhH2COOC
N OPhH2COOC
NO COOCH2Ph
Rh
Rh2(5S-BEPY)4
MS 4Å
CH2Cl2, rt
 
Scheme 4.7 
 
In a recent publication from Doyle’s group, a mixed-valent dirhodium(II, III) 
caprolactamate is used as a catalyst in aziridinations of alkenes.183 This catalyst is 
formed by reacting dirhodium(II) caprolactamate [Rh2(cap)4] 77 with NBS (N-
bromosuccinimide) in a one-electron oxidation, yielding the paramagnetic mixed-valent 
complex 78. Scheme 4.8 demonstrates this redox process, with simplified rhodium 
complex structures (only one of the four caprolactam units is drawn).  
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Scheme 4.8 
 
The basis for this catalyst’s effectiveness is the ability to undergo facile atom-transfer 
redox chemistry (Rh24+/Rh25+) because of its low one-electron oxidation potential.184 In 
a combination with NBS, p-toluenesulfonamide and potassium carbonate, a range of 
aziridines were synthesised by the group of Doyle. Scheme 4.9 exemplifies two of the 
specific aziridination reactions. 
 
 
Scheme 4.9 
 
A closer study of the catalysts role has also revealed that no nitrene intermediate is 
present in reactions of this kind. On the other hand, an ionic mechanism is found to be 
operative. Mechanistically, catalyst 78 operates as a Lewis acid and is capable of 
generating other potentially useful intermediates. If we consider the proposed 
mechanism in Scheme 4.10, we first observe that NBS and TsNH2 are found to be in an 
equilibrium with TsNHBr and succinimide (1). By the addition of a base (K2CO3), the 
equilibrium is shifted towards the deprotonated salt of potassium bromotosylamide (2).       
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Scheme 4.10 
 
The mixed-valent rhodium complex (78) is thought to function as a Lewis acid to 
activate residual amounts of NBS and/or TsNHBr, catalysing electrophilic bromonium 
ion transfer to an alkene. Capture of TsNH2 (or KNTsBr) makes up the structural motif, 
which is able to spontaneous ring-close to the aziridine (3). Whether or not the mixed-
valent complex 78 plays another vital role in the reaction, beyond as Lewis acid 
catalyst, remains uncertain. 
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4.2 Retrosynthesis 
The strategy of catalytic asymmetric aziridination is based on the retrosynthetic strategy 
described in Scheme 4.11. 
 
R
O
R
R
N X
R
H
N
XR
NH2
Substituted (S)-2-AMT
Substituted -tetralon Substituted 1,2-dihydronaphthalene
Substituted (1R,2S)-aziridine
X = N protecting group
 
Scheme 4.11 
 
In the first part of the strategy, 1,2-dihydronaphthalenes are synthesised from 
commercial -tetralones. This can be performed through a two-step reduction and 
dehydration process. In the next step, chirality is induced through an asymmetric 
aziridination. Testing of various catalysts, modified upon known procedures, will be the 
major focus in this part of the thesis. Further, ring-opening of the aziridine and finally 
an N-deprotection, should liberate the substituted (S)-2-aminotetralin derivatives.    
 
The target molecules for the strategy were 2-aminotetralin and the 6- or 7-methoxy 
substituted analogues, shown in Figure 4.2.   
 
 
Figure 4.2: Target molecules 
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4.3 Results and discussions 
4.3.1 Synthesis of 1,2-dihydronaphthalenes 
Substituted 1,2-dihydronaphthalenes were synthesised from their respective -
tetralones, all commercially available. The two-step reaction involves a reduction to an 
alcohol with NaBH4 followed by an acid catalysed dehydration reaction, which is based 
on a procedure described by Hauser and Prasanna (Scheme 4.12).185       
 
O
NaBH4
pTsOH
OH
R2
R1
R2
R1
R2
R1
50: R1=H, R2=H
51: R1=MeO, R2=H
52: R1=H, R2=MeO
53: R1=H, R2=H
54: R1=MeO, R2=H
55: R1=H, R2=MeO
56: R1=H, R2=H
57: R1=MeO, R2=H
58: R1=H, R2=MeO
EtOH,
Toluene,
Azeotropic
removal of
water
 
Scheme 4.12 
The 1,2-dihydronaphthalenes 56, 57 and 58 were synthesised in 76%, 90% and 97% 
yield, respectively.  
 
In the attempts to perform an asymmetric aziridination reaction on 6-methoxy-1,2-
dihydronaphthalene (57), we encountered some problems. They will be discussed in 
detail in chapter 4.3.3, but the outcome resulted in the synthesis of another 6-substituted 
analogue of compound 57. We decided to synthesise the 6-acetoxy analogue 62 from 
commercially available alcohol 59. Two strategies were evaluated, differing only in the 
order of the acylation reaction, prior or after the two-step transformation. Both methods 
were attempted (Scheme 4.13). 
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Scheme 4.13 
 
Initial tests demonstrated that method A was the only successful approach, since method 
B failed to provide any product. However, several improvements in method A were also 
found to be necessary due to low yield. This was mainly ascribable to the 
reduction/dehydration conditions, since acyltetralone 60 was formed in almost 
quantitative yield. After replacing p-toluenesulfonic acid by the weaker oxalic acid 
(pTsOH: pKa -2.8, oxalic acid: pKa1 1.25186), and changing the solvent from toluene to 
benzene, a yield of 37% was obtained for 6-acetoxy-1,2-dihydronaphthalene (62).               
 
An alternative approach towards compound 62 was performed by utilising the Shapiro 
reaction.187 By reacting the tetralone 59 with tosylhydrazin in refluxing ethanol, the 
tosylhydrazone 63 was isolated in 86% yield following a procedure by Baldwin and 
Krauss.188 Unfortunately, the Shapiro reaction, i.e. synthesis of 61, proved to be rather 
unsuccessful (Scheme 4.14).  
 
 
Scheme 4.14 
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Both diethyl ether and THF were attempted as solvents in the synthesis of 61, but 
neither provided any products in good yields. Acylation of 61 resulted in a number of 
different products according to TLC, thus we decided to terminate any further attempts 
with the Shapiro reaction.    
 
4.3.2 Preparation of [N-(arenesulfonyl)imino]phenyliodinanes 
Three various nitrene precursors in the class of [N-(arenesulfonyl)imino]phenyl-
iodinanes were synthesised, following a modified procedure described by Brandt and 
co-workers (Scheme 4.15).178  
 
 
Scheme 4.15 
 
In these reactions, the products gradually crystallised out of the cold crude mixture, and 
they were finally washed with cold methanol. Following the original procedure by 
Yamada and co-workers, introducing water to the crude mixtures significantly lowered 
the yields (68: 62%, 69: 72%, 70: 38%).170     
 
4.3.3 Racemic aziridination by rhodium catalysts  
Racemic aziridines were prepared for chiral analysis purposes according to Doyle’s 
Rh2(cap)4/NBS/TsNH2 protocol.183 A summary of the results are presented in Scheme 
4.16 and Table 4.1. 
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Scheme 4.16 
Table 4.1: Synthesis of racemic aziridines 
Entry Substrate ArSO2NH2 Product Yield (%) 
1 56 64 71 92 
2 56 65 72 30 
3 56 66 73 76 
4 57 64 74 4a 
5 58 64 75 54 
6 62 64 76 63 
 a) Isolated as a mixture with other products. 
 
Suitable chiral HPLC-systems for the analytical separation of aziridine enantiomers (71-
76) were developed, and implemented in the work of asymmetric aziridinations.        
 
One result that strongly deviated from the others was the aziridination of the methoxy 
substituted substrate 57 (Entry 4). The reaction was monitored and showed a full 
conversion prior to the column chromatography, but only a small impure amount of 
aziridine 74 was isolated. A plausible explanation can be ascribed to the electron 
donating methoxy group in the 6-position, which may contribute to resonance 
stabilisation of the benzylic carbocation that is formed in the aziridine ring opening. 
Compared to aziridine 75 (Entry 5), with the methoxy group in the 7-position, no 
conjugated stabilisation of the carbocation is possible. Scheme 4.17 illustrates this 
theory in a ring opening mechanism, which eventually adds a molecule of water or 
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alternatively another nucleophile present in the reaction mixture to provide the 
intermediate carbocation.  
 
 
Scheme 4.17 
 
To circumvent this stability problem, we decided to synthesise the aziridine analogues 
76 and 84 (see Scheme 4.21 for structures), equipped with an acetoxy substituent on the 
expense of the methoxy. This was based on the prediction that an electron withdrawing 
group like acetoxy would not stabilise the ring opened carbocation like the one 
described in Scheme 4.17. Another factor was the possibility of transforming the 
acetoxy- into a methoxy-function, in the final 2-aminotetralin product 96 (Figure 4.2).   
 
Synthesis of enantioenriched aziridines were attempted using one of Doyle’s chiral 
dirhodium catalysts, i.e. Rh2(5S-MEPY)4 (79). As for the synthesis of racemic 
aziridines, we decided to test the same protocol, but utilising this chiral catalyst.183 
Scheme 4.18 and Table 4.2 summarises the results of these reactions. 
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Rh2(5S-MEPY)4 (79)  
Scheme 4.18 
Table 4.2: Asymmetric aziridination catalysed by a chiral dirhodium complex 
Entry ArSO2NH2 Temp 
(ºC) 
Time 
(h) 
Product Yielda 
(%) 
 % eeb 
1 64 20 18 71 90 0 
2 64 -20 72 71 56 0 
3 64 -78 96 71 50 0 
4 65 20 18 72 60 0 
5 66 20 18 73 47 0 
 a) Isolated yield from column chromatography. 
 b) The enantiomeric excess of the products was determined by HPLC. 
 
The aziridination protocol provided no enantiomeric excess.   
4.3.4 Copper catalysed asymmetric aziridination 
Asymmetric aziridination of various alkenes were attempted with the bidentate ligand 
PhBOX (80) and Cu(OTf)2 as catalyst, following Evans procedure.172 The reaction was 
performed at different temperatures and with three types of nitrene donors 68-70 
(Scheme 4.19, Table 4.3).  
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Scheme 4.19 
Table 4.3: Asymmetric aziridination by PhBOX (80)/Cu(OTf)2 catalysis 
Entry Substrate Nitrene 
precursor 
Temp 
(ºC) 
Time 
(h) 
Product Yielda 
(%) 
 % eeb 
1 56 68 20 36 71 16 30 
2 56 69 20 36 72 26 37 
3 56 70 20 36 73 22 36 
4 56 68 -20 72 71 22 36 
5 56 69 -20 72 72 16 16 
6 56 69 -78 96 72 16 41 
7 58 68 20 36 75 -c - 
8 58 68 -20 72 75 -c - 
9 62 68 -20 72 76 -d - 
 a) Isolated yield after column chromatography. 
 b) The enantiomeric excess of the products was determined by HPLC. 
 c) Only 2-methoxynaphthalene was identified as product from the reaction. 
 d) No reaction observed. 
 
Table 4.3 shows that only the unsubstituted alkene 56 gave the corresponding aziridine 
utilising PhBOX as a chiral ligand, however in quite low yield. The enantiomeric excess 
was also relatively moderate (Entry 1-6, 16-26% yield, 16-41% ee). These were quite 
discouraging results, compared to other substrates published by Evans and co-workers, 
where the same protocol (PhBOX (80)/Cu(OTf)2) was used.172 In general they reported 
higher yields (60-76%) as well as higher enantioselectivity (>90% ee) for the 
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aziridination reactions of unfunctionalised olefins. The 7-methoxy substituted alkene 58 
underwent a different reaction (Entries 7 and 8), resulting in an aromatised naphthalene, 
i.e. 2-methoxynaphthalene. In the case of 6-acyl alkene 62 (Entry 9), no reaction took 
place.  
 
In another series of asymmetric aziridinations, following Jacobsen’s procedure,177 
various chiral ligands were tested, i.e. t-BuBOX (81), Jacobsen’s diimine ligand 82 and 
Bolm and Simi	’s ligand 83 (Scheme 4.20). The latter ligand 83 has previously not been 
reported in aziridination attempts. In copper catalysed asymmetric hetero-Diels-Alder 
reactions however, excellent yields and selectivities have been reported.189 Based on 
this, we decided to test it in parallel to the well known Evans and Jacobsen’s catalytic 
systems. In addition to variations in reaction conditions, alternative copper-salts were 
tested, i.e. [(CH3CN)4Cu]PF6 (simplified form is [Cu]PF6), as well as the previously 
used copper triflate. The results of these experiments are shown in Scheme 4.20 and 
Table 4.4.  
 
The best results were provided by a catalytic system with Jacobsen’s diimine ligand 82, 
[Cu]PF6 and nitrene precursor 68 (Entry 1-4). Isolated yields up to 82% were obtained, 
with enantioselectivity values up to 87% ee. Through further recrystallisation, excellent 
enantiopurity was achieved (up to 98% ee). Attempts with Bolm and Simi	’s ligand 83 
(Entry 5-6) failed to provide a decent yield (10-14%), and BuBOX 81 resulted only in 
traces of product. Switching to copper(II)triflate in combination with ligand 81 or 83 
was also completely unsuccessful (Entry 8-10). Finally, changing the nitrene precursor 
from tosyl 68 to nosyl 69 (Entry 11-12), gave low yields ranging from 33 to 36%.  
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Scheme 4.20 
Table 4.4: Copper catalysed asymmetric aziridination of 56 with various ligands  
Entry Nitrene 
precursor 
Cu salt L* Temp 
(ºC) 
Time 
(h) 
Prod Yielda 
(%) 
 % eeb 
1 68 [Cu]PF6 82 -40 24 71 47 75 
2 68 [Cu]PF6 82 -40 48 71 82, 47c 87, 98c
3 68 [Cu]PF6 82 -20 24 71 63, 31c 65, 98c
4 68 [Cu]PF6 82 -40 72 71 63 75 
5 68 [Cu]PF6 83 -40 24 71 10 17e 
6 68 [Cu]PF6 83 -20 48 71 14 14e 
7 68 [Cu]PF6 81 -40 48 71 traces - 
8 68 Cu(OTf)2 81 -20 24 71 traces - 
9 68 Cu(OTf)2 81 -40 48 71 -d - 
10 68 Cu(OTf)2 83 -40 48 71 -d - 
11 69 [Cu]PF6 82 -40 24 72 33 53 
12 69 [Cu]PF6 82 -20 24 72 36 34 
 a) Isolated yield after column chromatography. 
 b) The enantiomeric excess of the products was determined by HPLC. 
 c) Isolated yield/% ee after crystallisation from EtOAc. 
 d) No reaction observed. 
 e) Abs. configuration (1S,2R)-for major isomer. 
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The best conditions from the results above were tested for the acetoxy substituted 
alkene 62. These results are presented in Scheme 4.21 and Table 4.5.  
 
 
Scheme 4.21 
Table 4.5: Asymmetric aziridination of 6-acetoxy-3,4-dihydronaphthalene (62)  
Entry Nitrene 
precursor 
Temp 
(ºC) 
Time (h) Prod Yielda 
(%) 
 % eeb 
1 68 -40 24 76 6 63 
2 68 -20 48 76 56 55 
3 68 -40 48 76 39, 31c 60, 66c 
4 69 -40 48 84 21 35 
 a) Isolated yield after column chromatography. 
 b) The enantiomeric excess of the products was determined by HPLC. 
 c) Isolated yield/% ee after crystallisation from EtOH. 
  
A moderate yield of 56% was obtained when utilising nitrene precursor 68, and 
enantiomeric enrichment through recrystallisation proved to be more difficult for 
compound 76 (Entries 2-3). Nitrene precursor 69 did not improve the reaction outcome 
either (Entry 4).    
 
Similar experiments were performed on 7-methoxy alkene 58. The results from these 
experiments are shown in Scheme 4.22 and Table 4.6. 
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Scheme 4.22 
Table 4.6: Asymmetric aziridination of 7-methoxy-3,4-dihydronaphthalene (58)  
Entry Nitrene 
precursor 
Temp 
(ºC) 
Time (h) Prod Yielda 
(%) 
 % eeb 
1 68 -20 48 75 53 64 
2 69 -20 48 75 24d 45d 
3 68 -40 48 75 33 66 
  4c 68 -40 48 85 34 50 
 a) Isolated yield after column chromatography. 
 b) The enantiomeric excess of the products was determined by HPLC. 
 c) Large scale experiment (5.6 mmol 58) with half the amount of catalyst (5 mol %). 
 d) Recrystallisation from EtOAc/n-hexane afforded 75 in 13% yield and 5% ee. Concentration of 
      the filtrate yielded enantiomerically enriched 75 (91% ee) in 10% yield. 
 
Analogue to previous results, nitrene precursor 69 provided lower yields and 
enantioselectivity compared to 68 (Entry 1 and 2).  The result of the asymmetric 
synthesis of aziridine 75 is comparable with the one described for aziridine 76 (Table 
4.2, Entry 2). Attempts to increase the ee of the products through recrystallisation of 75, 
also failed.    
 
The configurations given in chapter 4.3.4 are based on analysis of the applied catalyst, 
and by comparing the stereochemical results obtained with substrates 56 and 58 
affording aziridines 71176 and 75 with known configuration. Abs. configuration for 75 
was established by chemical correlation with the known trifluoroacetylaminotetralin 39 
(see Chapter 4.3.7).91  
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4.3.5 Asymmetric aziridination by ruthenium catalysts 
Inspired by the results from Katsuki’s ruthenium(salen)CO complexes180 presented in 
chapter 4.1.3, we decided to test similar complexes in the aziridination of alkene 56.  
However, Katsuki’s ruthenium complexes are not commercially available and they 
appear to be quite labour intensive to synthesise. Therefore we decided to test simpler 
ruthenium complexes equipped with substituted benzene rings, compared to Katsuki’s 
substituted binaphthyl system.  
 
Complexes 88 and 89 were attempted synthesised by reacting Ru3(CO)12 with the 
respective chiral ligands H2[3,5-Cl2-salen] (86) and H2[3,5-tBu2-salen] (87), utilising 
the method described by Katsuki and co-workers (Scheme 4.23, Table 4.7).180   
  
 
Scheme 4.23 
Table 4.7: Preparation of Ru-complex 88 and 89 by Katsuki’s method  
Entry Ligand Product Ligand/ 
Ru3(CO)12a 
Solvent Time 
(d) 
Yieldb 
1 87 89 0.67 : 1 EtOH  1 - 
2 86 88 0.74 : 1 EtOH  2 - 
3 86 88 0.72 : 1 Toluene  1 - 
4 86 88 1 : 1 EtOH  2 - 
 5 86 88 2.5 :1  EtOH  5 - 
 a) Ratio ligand: Ru3(CO)12. 
 b) No yield provided. 
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All five experiments (Entry 1-5) all failed to provide the target complexes 88 and 89, 
respectively. Variations in the ligand/Ru-source ratio, changing to dried solvent quality 
and longer reaction times were totally unsuccessful.   
 
Another synthetic approach towards the formation of complexes 88 and 89 was 
investigated. The methodology was based on Che’s method, which consists of a two 
step process.190 First, the salen ligand (86 or 87) was reacted with a ruthenium(II) 
source ([Ru(PPh3)2(Cl)2]) under basic conditions (Et3N). Second, the crude mixture was 
treated with CO-gas, to introduce the CO-ligand (Scheme 4.24).   
 
N N
R R
R R
O O
Ru
CO
[Ru(PPh3)2Cl2]
88: R = Cl; [Ru(3,5-Cl2-salen)(CO)]; 43% yield
89: R = tBu; [Ru(3,5-tBu2-salen)(CO)]; no product
[Ru(3,5-R2-salen)]+ H2[3,5-R2-salen]
86: R = Cl
87: R = tBu
NEt3 CO (1 atm)
MeOH
, 19 h
DCM
rt, 16 h
 
Scheme 4.24 
While we were able to synthesise 88 in a yield of 43% (Che and co-workers reported 
66% yield), attempts to prepare the tBu analogue 89 was unsuccessful. The latter has 
not been reported in literature either.   
 
Asymmetric aziridination of alkene 56 with three various Ru-catalysts were attempted, 
based on Katsuki’s procedure.180 As a nitrene precursor, p-toluenesulfonyl azide (TsN3) 
was used (except for Entries 3 and 4, where 68 was used). This precursor was prepared 
from p-toluenesulfonyl chloride and NaN3 by a method published by Ghosh and co-
workers.191 Beside complex 88, which is already described thoroughly, we decided to 
test two other Ru-complexes (90 and 91) currently available within the research group. 
Previously, these Lewis acid catalysts have been tested in asymmetric Diels-Alder 
reactions between enals and dienes.192 These two complexes are also chiral, unsaturated 
16-electron Ru-complexes, if we consider acetone to be only loosely coordinated to the 
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metal centre. Scheme 4.25 and Table 4.8 summarises the asymmetric aziridination 
experiments catalysed by the various ruthenium-complexes.  
N
56
Ts
71
Ru-catalyst (78, 80 or 81)
TsN3 or 68
DCM, MS 4Å
OPh
Ph O
P
P
Ru
O
C6F5 C6F5
C6F5 C6F5
+ SbF6
_
OPh
Ph O
P
P
Ru
C6F5 C6F5
C6F5 C6F5
+ OTf
_
9190
N N
Cl Cl
Cl Cl
O O
Ru
CO
88
O
 
Scheme 4.25 
Table 4.8: Asymmetric aziridination by chiral Ru-catalysts 
Entry Ru-catalyst Nitrene donor Time (h) Product 71 
1 90 TsN3 24 - 
2 91 TsN3 24 - 
3 90 PhI=NTs (68) 48 - 
4 91 PhI=NTs (68) 48 - 
5 88 TsN3 24 - 
6 88 TsN3 48 - 
 
Unfortunately, non of the catalytic systems (Entry 1-6) provided the desired aziridine 
derivative 71. The two ruthenium catalysts 90 and 91 were tested primarily due to 
availability, and exist in a quite different geometry and electronic configuration 
compared to Katsuki’s salen-complexes.180 Negative results in Entry 1-4 were easily 
accepted based on modest expectations, since no such structurally related Ru-
compounds have been reported in aziridination reactions. On the other hand, catalyst 88 
can be considered to be a simplified version of Katsuki’s complex, where disubstituted 
phenyl rings are replaced by monosubstituted binaphthyls. This substitution pattern 
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should not dramatically alter the electronic properties of the metal, and based on this we 
expected 88 as a potential catalyst in the aziridination reaction (Scheme 4.25). Analyses 
of the reactions (Entries 5-6) showed that no reaction occurred. This might indicate that 
activation through higher temperature or UV-irradiation is necessary to initiate the 
reaction. However, compared to the results by Katsuki and co-workers, such activation 
should not be required. Another question is the choice of solvent. While DCM was the 
solvent of choice for Katsuki’s aziridinations, complexes 88, 90 and 91 were sparingly 
soluble in DCM. This difference can be ascribed to the larger organic binaphthyl 
moieties in Katsuki’s complex, resulting in a higher DCM solubility.    
 
4.3.6 Ring opening reactions of aziridines by catalytic hydrogenation 
The aziridines 71, 75 and 76 were ring opened by a procedure developed by Tanner and 
Gautun,63 in which the aziridine ring is subjected to hydrogenolysis of the benzylic C-N 
bond. The reaction is highly regioselective because of the potential of 
carbocation/radical stabilisation in the benzylic position. Scheme 4.26 and Table 4.9 
summarises the results of the ring opening reactions. 
 
The results of the catalytic hydrogenations (Entry 1-6) demonstrate clearly that these 
reactions are both clean and regioselective. In all cases, almost quantitative yields were 
obtained after a simple filtration of the crude mixture. Based on the results obtained for 
(1R, 2S)-76 (Entry 4), we decided to terminate our work towards target molecule 96.  
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N
Ts
R2
R1
N
Ts
R2
R1
(1R, 2S)-71: R1 = H, R2 = H
(1R, 2S)-76: R1 = OAc, R2 = H
(1R, 2S)-75: R1 = H, R2 = OMe
(1S, 2R)-71: R1 = H, R2 = H
(1S, 2R)-76: R1 = OAc, R2 = H
(1S, 2R)-75: R1 = H, R2 = OMe
+
R2
R1
(2S)-92: R1 = H, R2 = H
(2S)-93: R1 = OAc, R2 = H
(2S)-25b: R1 = H, R2 = OMe
R2
R1
(2R)-92: R1 = H, R2 = H
(2R)-93: R1 = OAc, R2 = H
(2R)-25b: R1 = H, R2 = OMe
H
N
H
N
Ts
Ts
+
Pd-catalyst
H2 (1 atm)
96% EtOH
 
Scheme 4.26 
Table 4.9: Ring opening of aziridines by catalytic hydrogenation 
Entrya Aziridine  
(% ee) 
Time  
(h) 
Product Yieldb 
(%) 
% eec 
1 (rac)-71 1 (rac)-92 95 - 
2 (1R, 2S)-71 (98% ee) 1 (2S)-92 99 98 
3 (rac)-76 0.5 (rac)-93 99 - 
4 (1R, 2S)-76 (55% ee) 0.5 (2S)-93 97 45 
5 (rac)-75 0.5 (rac)-25b 97 - 
6 (1R, 2S)-75 (56% ee) 0.5 (2S)-25b 98 60 
 a) 10 mol % catalyst (Pd/C) were used in all reactions. 
 b) Isolated yield after column chromatography. 
 c) The enantiomeric excess of the products was determined by HPLC. 
 
 
4.3.7 Deprotection of tosyl amides 
In order to achieve our target amines 94 and 27, we needed to remove the tosyl 
protecting groups. Our first attempt was done by a Tanner and Somfai protocol, utilising 
excess sodium naphthalide as a one electron reductant (Scheme 4.27).193  
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Scheme 4.27 
Unfortunately, no reaction was observed under these conditions. This might be due to 
non-satisfactory dryness of our reaction conditions. A deep blue/green colour induced 
by the naphthalide anion should be present during the progress of the reaction, but in 
this case the solution turned yellow after the addition of tosylamide 92.  
 
In a second approach, the reaction was attempted via a reactive secondary tosylamide, 
prior to the reaction with Na-naphthalide. This was performed by reacting 92 with 
TFAA under basic conditions, following a procedure by Moussa and Romo.194 The bis-
protected intermediate, was not isolated, but used directly (Scheme 4.28). 
 
 
Scheme 4.28 
 
Again we were not able to liberate the amine function, and the sodium naphthalide 
approach was terminated.    
 
In a third approach we tested the Moussa and Romo protocol, where samarium(II)iodide 
is used as a mild and efficient one electron reducing agent.194 Again, an intermediate 
reactive bis-protected amine was prepared in situ by a reaction with TFAA, followed by 
the addition of the reducing agent (Scheme 4.29 and Table 4.10). 
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Scheme 4.29 
Table 4.10: Removal of the tosyl protecting groups 
Entry Tosylate  
(% ee) 
Product Yielda  
(%) 
% eeb 
1 (2S)-92 (98) (2S)-95 82 98 
2 (2S)-25b (56) (2S)-39 85 56 
 a) Isolated yield after column chromatography. 
 b) The enantiomeric excess of the products was determined by HPLC. 
  
 
The reductive conditions successfully removed the tosyl moiety, resulting in the 
formation and isolation of trifluoroacetamides 95 and 39. The base labile protection 
group was successively removed by aqueous base treatment with K2CO3 in up to 
quantitative yields ((2S)-94: 81% yield and (2S)-27: >99% yield), following a procedure 
by Gómez-Sánches and co-workers.151  
 
Finally, in a very recent publication by Ankner and Hilmersson, the deprotection takes 
place without the need of preparing the intermediate bis-protected amine. In this 
procedure, samarium(II)iodide instantly deprotects and liberates the free amine.137 
Results from utilising this protocol have already been presented in chapter 2.3.9.     
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4.4 Summary 
Three 1,2-dihydronaphthalene derivatives were successfully synthesised as substrates 
for the asymmetric aziridinations in up to 97% yield. The 6-methoxy isomer 57 was 
replaced by the 6-acetoxy isomer 62, since we were not able to produce 6-methoxy-
aziridine 74.    
 
Synthesis of racemic aziridines 71-76 were performed according to Doyle’s 
Rh2(cap)4/NBS/TsNH2 protocol. We were able to obtain acceptable yields (30-92%) for 
the purpose of analytical references (HPLC analyses of % ee). The very same reaction 
protocol was also tested with the chiral dirhodium catalyst Rh2(5S-MEPY)4, only to 
provide racemic mixtures (47-90% yield).  
 
Asymmetric aziridination attempts with various copper sources (Cu(OTf)2 and 
[(CH3CN)4Cu]PF6), ligands (Evans bis(oxazolines), Jacobsen’s diimines and Bolm and 
Simi	’s ligand) and nitrene precursors ([N-arenesulfonyl)imino]phenyliodinanes) were 
attempted. We were able to obtain up to 82% yield (87% ee) for the non-substituted 
alkene 56 (98% ee after recrystallisation), but only low to mediocre aziridination yields 
were achieved for 6-acetoxy-alkene 62 (6-39%, 35-63% ee) and 7-methoxy-alkene 58 
(24-53%, 45-66% ee).  
 
Three ruthenium ligands were also tested in asymmetric aziridination according to a 
protocol by Katsuki. Unfortunately these systems were unable to deliver any products.    
 
Ring opening of aziridines by catalytic hydrogenation was performed smoothly in high 
yields (>95%). Improved methods for the deprotection of N-tosyl groups, under mild 
conditions, provided good yields (up to 85%) in the final step.    
 
To reach the goal of establishing an efficient catalytic system for asymmetric 
aziridination of substituted 1,2-dihydronaphthalenes, new catalysts should be evaluated.      
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4.5 Experimental 
The full experimental description for Chapter 4 is reported in Paper III.  
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1. Introduction  
The pharmacological activity of 2-aminotetralin (2-amino-
1,2,3,4-tetrahydronaphthalene, AT) was first described by 
Bamberger and Filehne in 1889.1 Since then a large number of 
articles and patents, mostly describing studies of the 
physiological properties of this class of compounds, have 
appeared.2  
 
 
 
 
 
 
 
 
 
Fig. 1. Pharmacological active 2-aminotetralins. 
Today, several enantiopure ATs are used in the treatment of 
medical conditions like Parkinson’s disease,3 glaucoma4 and 
septic shock5,6 (Fig. 1).  
Recently, we reported the synthesis of substituted (S)-ATs via 
ring-opening of aziridine 1a prepared from L-aspartic acid -tert-
butyl ester (see Scheme 1).7 Unfortunately, this protocol was 
accompanied with a disturbing elimination reaction. In order to 
circumvent this side reaction we have tested an alternative chiral 
C4-aziridine building block, 1b, as shown in the protocol 
described in Scheme 2. 
 
 
 
 
 
 
 
Scheme 1. 
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This paper describes a new total synthesis for (S)-2-amino-7-methoxytetralin, (S)-7-MeO-AT,
from L-aspartic acid in an overall yield of 11% over nine steps. The major loss was ascribed to a
key intramolecular Friedel-Crafts cyclisation step, which afforded up to 36% yield. Attempts to
perform Friedel-Crafts cyclization of an intermediate phthalimide protected amino alcohol 13
did not give the desired protected (S)-7-MeO-AT. On the other hand, two new isoindolo[1,2-
a]isoquinolinone derivatives 14 and 15, were isolated in 11 and 21% yield, respectively. 
2010 Elsevier Ltd. All rights reserved.
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Scheme 2. Strategy for enantioselective synthesis of (S)-2-
amino-7-methoxytetralin, (S)-7-MeO-AT, from L-aspartic 
acid.  
 
In the presented study (S)-2-amino-7-methoxytetralin, (S)-7-
MeO-AT, was chosen as the target molecule. The protocol does, 
however, have the potential to offer ATs with other subtstiutents 
on the aromatic ring. 
 
2. Results and discussion 
2.1. Preparation and  ring-opening of aziridine 1b  
Natural L-aspartic acid (L-Asp) served as starting material in a 
three step synthesis to N-Boc-diol 2, following literature 
procedures (Scheme 3).8,9 Ring-closing of N-Boc-diol 2 to 
aziridine 1b was performed according to an adopted procedure 
described by Wessig and Schwartz.10 In addition to the 
intermediate ditosylate 3, the reaction afforded 1b as the only 
cylized product.   This observation was a contrast to the tosylated 
(or mesylated) N-Boc--amino alcohols tendency to form 
oxazolinones.11,12 We were not able to observe any azetidine 
formation either, which might occur in some cases where three- 
and four-membered ring formation are competitive pathways.13 
 
 
 
 
 
 
 
 
Scheme 3.  
 
Ring-opening reaction of N-Boc-aziridine 1b by a copper aryl 
nucleophile {from (3-methoxyphenyl)magnesium bromide and 
CuBr·Me2S} provided compound 4 in a decent yield. However, 
the product proved to be somewhat unstable at room temperature. 
Refluxing of 4 in THF and DCM for 6 hours gave 50% and 23% 
decomposition respectively. As a consequence, product 4 was 
stored in an inert atmosphere at 
18 °C. 
 
2.2. Intramolecular Friedel-Crafts alkylation  
 Little is known about the possibilities for intramolecular 
Friedel-Crafts alkylation of alkyl tosylates, or compounds 
holding other sulfone based leaving groups (e.g. mesyl or 
triflate). Initial efforts to ring-close tosylate 4 in the presence of 
TiCl4 in DCM gave rapid cleavage of the Boc-group even at 
room temperature. No AT products were observed. A 
trifluoroacetyl group was therefore introduced to double protect 
the amine function in 4 (see Scheme 4). Attempted Friedel-Crafts 
cyclisation of 5 under the same conditions did, however, give 
cleavage of the Boc-group as well as halogen exchange of the 
tosyl group, resulting in chloride 6. A similar exchange has been 
reported with oxophilic Lewis acids in the presence of alkyl 
tosylates.14  
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Scheme 4. (a) TFAA, Et3N, DCM, 0 ºC – rt. 99% yield. (b) 
TiCl4, DCE, 80 °C, 58% yield. (c) NaI, acetone, 35 °C, 12 h. 
78% yield.  
 
The newly formed alkyl chloride 6 could, however, serve as a 
substrate for a classical Friedel Crafts alkylation reaction. The 
corresponding iodide 7 was prepared for comparison (see 
Scheme 4). The results of the cyclisation reactions of chloride 6 
and iodide 7 are summarised in Table 1. 
 
 
Table 1. Intramolecular Friedel-Crafts alkylation  
 
 
 
 
 
 
Entry 
 
Substrate 
 
Lewis 
acid 
 
Conditions,
solvent 
 
Ratio e  
8  :  9     
 
% yield 8,a 
(% ee) b 
1 6 AlCl3    
(2 equiv) 
80 °C, 7 h 
DCE       
 - c 
2 6 AlCl3    
(2 equiv) 
83 ºC, 20 h    
DCE 
 - c 
3 6 InBr3    
(2 equiv) 
83 ºC, 20 h    
DCE 
69 : 31 complex 
mixture 
4 6 AlCl3    
(3 equiv) 
100 ºC, 20 
h, DCM d 
83 : 17 36          
(99) 
5 6 InBr3    
(2 equiv) 
80 ºC, 20 h 
DCM d 
68 : 32 <15       
(99) 
6 6 SnCl4    
(3 equiv) 
80 ºC, 20 h 
DCM d 
 - c 
7 6 BF3.Et2O    
(3 equiv) 
80 ºC,  20 h 
DCM d 
 - c 
8 7 InBr3    
(2 equiv) 
80 ºC, 18 h 
DCM d 
71 : 29 26         
(97) 
 a Isolated yield after purification. b The enantiomeric excess of the products 
was determined by HPLC analysis. c No reaction. d Reaction performed in 
closed pressure tube. e Ratio determined according to 1H NMR spectrum of 
the product mixture. 
4
6: X = Cl, R = H
7: X = I, R = Boc
HN
9
Lewis acid
X
8
F3C O
HN
F3C O
OMe
OMe
+
N OMe
R
F3C O
2
H
N
Boc OH
OH
L-Asp
TsCl, KOH
lit. 3 steps
(76% yield)
Et2O, heat
H
N
Boc OTs
OTs
3
OTs
1b (76% yield)
H
N OMe
Boc
OTs
4 (80% yield)
3-MeO-C6H4MgBr/
CuBr SMe2
THF, -40 oC
N
Boc
 3
Two solvents and four Lewis acids were tested. Both, chloride 
6 and iodide 7 afforded the desired target molecule 8. 
Unfortunately, neither of them provided regioselective reactions, 
giving significant amounts of the 5-methoxy isomer 9 as well. 
We did not succeed in finding the optimal conditions for the 
reactions. The best selectivity (ratio 8 : 9 = 83 : 17) and yield (36 
% yield based on 1H NMR of the product mixture) of 8 was 
obtained with AlCl3 in DCM at 100 °C (closed glass pressure 
tube) for 20 hours (Table 1, entry 4). The products 8 and 9 were 
only partly separable by flash chromatography. 
Target molecule (S)-7-MeO-AT is accessible through basic 
hydrolysis of 8, by a procedure described by Gómez-Sánches et 
al.15 Hydrolysis of trifluoroacetylated amines are reported to 
provide up to quantitative yields.  
 
2.3. Preparation and cyclization of  phthalimide protected 
amino alcohol 13 
Harris et al.16 have reported preparation of ATs by ring-
closure of phthalimide protected isomere-13 (see Fig. 2). 
Treatment of isomere-13 with CF3SO3H in PhCl at 80 °C gave 
quantitive yield of ATs in an ortho : para ratio of 1 : 3. Inspired 
by their results, we aimed at preparing (S)-7-MeO-AT from the 
13, which was assumed to be available from 4.  
 
 
 
 
  
 
Fig. 2 Phthalimide protected AT precursors.     
 
Synthesis of PhthN-alcohol 13 was successfully provided via 
two alternative routes, according to Scheme 5.  
 
 
 
 
 
Scheme 5. (a) KOH, DMSO, rt, 18h, 60% yield. (b) (i) LiOH, 
MeOH/H2O, 70 ºC, 2 h. (ii) EtOH/conc HCl, rt, 65% yield. (c) 
SmI2, H2O, pyrrolidine, rt, 5 min, 32% yield. (d). Conc 
HCl/toluene, 65 ºC, 2 h, yield 80% (e) Phthalic anhydride, 
Et3N, toluene, , 24 h, 43% yield.  
 
Treatment of PhthN-alcohol 13 with triflic acid according to 
the procedure described by Harris et al.16 gave a product mixture 
which did not appear to contain significant amounts of the 
desired (S)-7-MeO-AT. We were, however, able to isolate two 
main products 14 and 15, shown in Scheme 6, which were 
structurally elucidated by NMR experiments (COSY, HSQC, 
HMBC, NOESY). A mechanistic suggestion for the formation of 
14 and 15 is given in Scheme 6. 
Compounds 14 and 15 can be classified in the isoindolo[1,2-
a]isoquinolinone family. This family contains one known natural  
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Scheme 6. Suggested mechanism for the formation of 
compounds 14 and 15. 
 
product, i.e. (±)-nuevamine, isolated from Berberis darwinii 
Hook species.17 Several approaches to synthesise derivatives 
of this class of compounds are known from literature.18-21 
Some of these compounds are considered to have potential 
biological activities.22 
 
3. Conclusion 
A new total synthesis for (S)-2-amino-7-methoxytetralin, (S)-
7-MeO-AT, from L-aspartic acid has been developed. The 
applied protocol afforded protected (S)-7-MeO-AT in an overall 
yield of 11% over nine steps. The major loss occurred in the step 
involving the intramolecular Friedel-Crafts cyclisation, for which 
only up to 36% yield was obtained, partially due to problems 
with separation of regioisomeric products. 
Attempts to perform Friedel-Crafts cyclization of the 
phthalimide protected alcohol 13 did not give the desired 
protected (S)-7-MeO-AT. On the other hand, this step afforded 
two new isoindolo[1,2-a]isoquinolinone derivatives 14 and 15, in 
11 and 21% yield, respectively. 
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OM 4. Experimental 
4.1. General 
All reactions were performed under an argon or nitrogen 
atmosphere. Tetrahydrofuran (THF) was distilled under nitrogen 
atmosphere from Na/benzophenone. Dichloromethane was 
distilled under nitrogen from calicium hydride. Melting points 
were determined on a Buchi 535 apparatus and are uncorrected. 
TLC was performed on Merck silica gel 60 F254 plates, using UV 
light at 312 nm and a 5% alcoholic molybdophosphoric acid for 
detection. Silica gel for flash chromatography was purchased 
from Merck. Optical rotations were measured with a Perkin-
Elmer 241 Polarimeter. Enantiomeric excesses were determined 
by HPLC analysis, using Daicels column Chiralcel OJ (250 x 4.6 
mm). 1H and 13C NMR spectra (Bruker Advance DPX 
instruments 300/75 MHz and 400/100 MHz) were obtained from 
solutions of CDCl3, and chemical shifts are in ppm and 
referenced to TMS via the lock signal of the solvent. 1H and 13C 
NMR signals were assigned by 2D correlation techniques 
(COSY, HSQC, HMBC, NOESY). IR spectra were run on a 
Thermo Nicolet FT-IR NEXUS instrument, and only the 
strongest/structurally most important peaks are listed. Accurate 
mass determination (ESI) was performed on an Agilent G1969 
TOF MS instrument equipped with a dual electrospray ion 
e
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source. Samples were injected into the MS using an Agilent 1100 
series HPLC and analysis was performed as a direct injection 
analysis without any chromatography.  
 
4.2. Preparation and ring-opening of aziridine 1b 
 
4.2.1 .  (S) - ter t -butyl  2- (2- tosy loxy)e thy l )az ir id ine-1-
carboxyla te  (1b ) .  
The title compound was prepared by adopting a procedure 
described by Wessig and Schwartz.10 Diol 28,9 (2.42 g, 11.8 
mmol) was dissolved in dry diethyl ether (180 mL) and added 
tosyl chloride (6.0 g, 31.5 mmol). Pellets of KOH (3.6 g, 65 
mmol) were grinded and added instantly to the mixture. After 24 
h of reflux, additional KOH (1.0 g, 18 mmol) was added. The 
reaction was quenched by pouring it over crushed ice (100 g). 
The organic layer was washed with brine (50 mL) and dried 
(MgSO4). Purification by flash chromatography (15% EtOAc in 
n-pentane) provided 3.08 g of 1b as a colorless oil (76 % yield). 
Data for 1b: Rf = 0.39 (EtOAc/n-hexane, 1:2).  D
22 +19.3 (1.0, 
CH2Cl2). 1H NMR (300 MHz):  7.80 (app d, J 8.0 Hz, 2H, 
tolyl), 7.35 (app d, J 8.0 Hz, 2H, tolyl), 4.25-4.12 (m, 2H, CH2-
O), 2.47-2.37 (m, 1H, CH-N), 2.45 (s, 3H, tolyl), 2.27 (d, J 6.0 
Hz, 1H, CHH-N), 1.92 (d, J 3.6 Hz, 1H, CHH-N), 1.93-1.71 (m, 
2H, CH2-CH2O), 1.43 (s, 9H, t-Bu). 13C NMR (100 MHz):  
162.1 (OC(=O)N), 144.9 (tolyl), 133.0 (tolyl), 129.9 (tolyl), 
127.9 (tolyl), 81.4 (t-Bu), 68.0 (CH2-O), 34.3 (CH-N), 31.9 
(CH2-CH2O), 31.4 (CH2-N), 27.9 (t-Bu), 21.6 (tolyl). IR (thin 
film, NaCl): 2979 (s), 1717 (s), 1598 (m), 1367 (s), 1309 (s), 
1222 (s), 1121 (m) cm-1. HRMS (ESI) calcd for C16H23NNaO5S 
(M+Na)+ 364.1189, found 364.1200.      
 
4.2.2 .  (R)-3-( ter t -butoxycarbonylamino)-4-(3-
methoxyphenyl )buty l  4-methylbenzenesul fonate  (4 ) .  
The title compound was made by adopting a procedure 
described by Burgaud and co-workers.23 A solution of 3-
bromoanisole (1.50 ml, 11.8 mmol) in anhydrous THF (8.5 mL) 
was added slowly to magnesium turnings (280 mg, 11.5 mmol) 
over a period of approximate 10 min. Once the addition was 
complete, the reaction was continued with vigorous stirring for 
30 min, then titrated utilizing salicylaldehyde as a titration 
indicator,24 and used immediately in the following reaction. A 
solution of Boc-aziridine 1b (535 mg, 1.57 mmol) and 
CuBr·Me2S (48 mg, 0.233 mmol, 15 mol %) in dry THF (25 mL) 
was cooled to 
40 °C under argon atmosphere. To the solution, a 
standardized amount the Grignard solution (3.14 mmol, 2 equiv) 
was added over a period of 5 min. The reaction mixture was 
stirred for 2 h and allowed to warm to 
10 °C. The reaction 
mixture was quenched by aqueous NH4Cl (saturated, 30 mL), 
warmed up to room temperature and extracted with diethyl ether 
(4 x 50 mL). The combined organic layer was washed with brine 
and dried (MgSO4). Purification performed by flash 
chromatography (15% EtOAc in n-pentane), yielded 4 (564 mg, 
80%) as a white crystalline material. Data for 4: Mp 74 - 77 °C 
(decomp. gas evolves), Rf = 0.33 (15% EtOAc in n-pentane). 
D 
22 
8.4 (1.0, CH2Cl2). 1H NMR  (400 MHz):  7.77 (app. d, J 
8.0 Hz, 2H, tolyl), 7.33 (app. d, J 8.0 Hz, 2H, tolyl), 7.19 (app. t, 
J 7.8 Hz, 1H, HAr-5), 6.76 (app. dd, J 7.8, 2.6 Hz, 1H, HAr-4), 
6.70 (app. d, J 7.8 Hz, 1H, HAr-6), 6.66 (app. s, 1H, HAr-2), 4.36 
(d, J 8.4 Hz, 1H, NH), 4.15-4.02 (m, 2H, H-1), 3.85-3.76 (m, 1H, 
H-3), 3.78 (s, 3H, CH3O), 2.85-2.76 (m, 1H, 1H, H-4), 2.69 (dd, 
J 13.2, 6.8 Hz, 1H, H-4), 2.44 (s, 3H, tolyl), 1.96-1.84 (m, 1H, H-
2), 1.82-1.66 (m, 1H, H-2), 1.38 (s, 9H, t-Bu). 13C NMR (100 
MHz):  159.7 (CAr-3), 155.1 (OC(=O)N), 144.8 (tolyl), 139.0 
(CAr-1), 132.9 (tolyl), 129.9 (tolyl), 129.5 (CAr-5), 127.9 (tolyl), 
121.7 (CAr-6), 115.0 (CAr-2), 112.1 (CAr-4), 79.0 (t-Bu), 67.9 (C-
1), 55.2 (CH3O), 48.8 (C-3), 41.0 (C-4), 33.2 (C-2), 28.3 (t-Bu), 
21.6 (tolyl). IR (KBr): 2929 (m), 1704 (s), 1600 (m), 1490 (s), 
1392 (s), 1292 (s), 1175 (s), 1097 (m) cm-1. HRMS (ESI) calcd 
for C23H32NO6S (M+H)+ 450.1945, found 450.1946. 
 
4.3. Intramolecular Friedel-Crafts alkylation 
4.3.1 .  (R)-3-( ter t -butoxycarbonyl ) -2 ,2 ,2- tr i f luoro-
acetamido-4-(3-methoxyphenyl )butyl  4-methyl -
benzenesul fonate  (5 ) .  
N-Trifluoroacetylation of tosylate 4 was performed according 
to a general protocol described by Moussa and Romo.25 Tosylate 
4 (450 mg, 1.00 mmol) was dissolved in DCM (20 mL) and 
cooled to 0 ºC, added Et3N (280 L, 2.01 mmol) followed by 
TFAA (280 L, 2.01 mmol). After vigorous stirring for 2.5 h at 
room temperature, the volatiles were removed under reduced 
pressure. The crude mixture was dissolved in DCM (50 mL), 
washed with aqueous NaHCO3 (saturated, 25 mL), aqueous citric 
acid (2% wt, 20 mL) and dried (MgSO4). Removal of the solvent 
yielded 5 (541 mg, 99%) as a relatively pure colorless oil. Data 
for 5: Rf = 0.37 (15% EtOAc in n-pentane). D 
23 +40.2 (1.0, 
CH2Cl2). 1H NMR  (400 MHz):  7.76 (app. d, J 8.4 Hz, 2H, 
tolyl), 7.33 (app. d, J 8.4 Hz, 2H, tolyl), 7.16 (app. t, J 7.9 Hz, 
1H, HAr-5), 6.75 (app. dd, J 7.9, 2.2 Hz, 1H, HAr-4), 6.68 (app. d, 
J 7.9 Hz, 1H, HAr-6), 6.64 (app. s, 1H, HAr-2), 4.75-4.60 (m, 1H, 
H-3), 4.15-3.90 (m, 2H, H-1), 3.76 (s, 3H, CH3O), 3.14 (dd, J 
13.6, 10.4 Hz, 1H, H-4), 2.85 (dd, J 13.6, 6.0 Hz, 1H, H-4), 2.43 
(s, 3H, tolyl), 2.40-2.29 (m, 1H, H-2), 2.11-2.00 (m, 1H, H-2), 
1.39 (s, 9H, t-Bu). 13C NMR (100 MHz):  160.5 (q, 2JC,F 39.2 
Hz, NC(O)CF3), 159.7 (CAr-3), 150.8 (Boc), 144.9 (tolyl), 138.2 
(CAr-1), 132.7 (tolyl), 129.9 (tolyl), 129.6 (CAr-5), 128.0 (tolyl), 
121.5 (CAr-6), 115.3 (q, 1JC,F 287.3, CF3), 114.5 (CAr-2), 112.8 
(CAr-4), 86.2 (Boc), 67.1 (C-1), 57.5 (C-3), 55.1 (CH3O), 38.7 
(C-4), 30.9 (C-2), 27.3 (Boc), 21.6 (tolyl). IR (thin film, NaCl): 
2985 (m), 1758 (m), 1713 (m), 1600 (m), 1456 (m), 1398 (m), 
1261 (m), 1144 (s), 1098 (m) cm-1.  
 
4.3.2 .  (R)-N-(4-chloro-1-(3-methoxyphenyl )butan-2-
y l ) -2 ,2 ,2- tr i f luoroacetamide  (6 ) .  
Double protected amine 5 (66 mg, 0.12 mmol) was dissolved 
in dry 1,2-dichloroethane (3.0 mL). Dropwise to this solution, 
TiCl4 (40 L, 0.365 mmol) was added, and the mixture was 
heated to 80 °C for 2.5 h. After cooling the mixture to room 
temperature, a phosphate buffer (pH 7, 10 mL, 1 M) was added. 
The mixture was diluted with DCM (20 mL) and the layers 
separated. The aqueous layer was extracted with additional DCM 
(2 x 10 mL). The combined organic layer was dried (MgSO4), 
filtrated and concentrated under reduced pressure. The residue 
was purified by flash chromatography (15% EtOAc in n-pentane) 
affording 6 (23 mg, 58%) as white solid. The white solid material 
could also be recrystallised (n-hexane/EtOAc) to fine crystalline 
needles. Data for 6: Mp 103 - 104 °C, Rf = 0.51 (15% EtOAc in 
n-pentane).  D
23 
24.6 (1.0, CH2Cl2). 1H NMR  (400 MHz):  
7.24 (app. t, J 7.9 Hz, 1H, HAr-5), 6.81 (app. dd, J 7.9, 2.4 Hz, 
1H, HAr-4), 6.74 (app. d, J 7.9 Hz, 1H, HAr-6), 6.70 (app. s, 1H, 
HAr-2), 6.31 (d, J 7.6 Hz, 1H, NH), 4.44-4.30 (m, 1H, H-2),  3.79 
(s, 3H, CH3O), 3.56 (t, J 6.6 Hz, 2H, H-4), 2.97-2.83 (m, 2H, H-
1), 2.17-1.95 (m, 2H, H-3). 13C NMR (100 MHz):  160.0 (CAr-
3), 156.9 (app. d, 2JC,F 35.7 Hz, C=O), 137.6 (CAr-1), 129.9 (CAr-
5), 121.6 (CAr-6), 115.7 (q, 1JC,F 289.3 Hz, CF3), 114.9 (CAr-2), 
112.6 (CAr-4), 55.2 (OCH3), 49.7 (C-2), 41.1 (C-4), 39.9 (C-1), 
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36.0 (C-3). IR (KBr): 3312 (m), 1704 (s), 1558 (m), 1487 (m), 
1439 (m), 1262 (m), 1156 (s), 1056 (m), 699 (m) cm-1.  
 
4.3.3 .  (R)- ter t -butyl  4- iodo-1-(3-methoxyphenyl ) -
butan-2-yl (2 ,2 ,2- t r i f luoroacety l )carbamate  (7 ) .  
The title compound was synthesized by adopting a procedure 
described by Saplay et al.26 Tosylate 5 (136 mg, 0.249 mmol) 
was dissolved in acetone (2.0 mL) and added NaI (70 mg, 0.467 
mmol). After vigorous stirring at 35 °C for 12 h, the solvent was 
removed under reduced pressure. The crude mixture was 
dissolved in water (10 mL) and DCM (15 mL), separated and 
additionally extracted with DCM (2 x 10 mL). After drying 
(MgSO4), the solvent was removed, and the residue purified by 
flash chromatography (10% EtOAc in n-pentane). Pure iodide 7 
was achieved in 78% yield as slightly yellow oil. Data for 7: Rf = 
0.65 (10% EtOAc in n-pentane). 1H NMR  (300 MHz):  7.19 
(app. t, J 7.9 Hz, 1H, HAr-5), 6.80-6.72 (m, 2H, HAr-4 and HAr-6), 
6.70 (app. s, 1H, HAr-2), 4.75-4.61 (m, 1H, H-2), 3.78 (s, 3H, 
CH3O), 3.21-3.01 (m, 3H, H-4 and H-1), 2.91 (dd, J 13.7, 6.2 Hz, 
1H, H-1), 2.62-2.47 (m, 1H, H-3), 2.27-2.13 (m, 1H, H-3), 1.42 
(s, 9H, t-Bu). 13C NMR (100 MHz):  160.2 (app. d, 2JC,F 44.9 
Hz, C(=O)CF3), 159.8 (CAr-3), 151.0 (OC(=O)N), 138.3 (CAr-1), 
129.6 (CAr-5), 121.5 (CAr-6), 115.4 (q, 1JC,F 288.3 Hz, CF3), 114.5 
(CAr-2), 112.7 (CAr-4), 86.2 (CMe3), 61.3 (C-2), 55.1 (CH3O), 
38.3 (C-1), 35.7 (C-3), 27.4 ((CH3)3C), 0.4 (C-4). IR (thin film, 
NaCl): 2984 (w), 1759 (m), 1713 (s), 1602 (m), 1586 (m), 1490 
(m), 1456 (m), 1372 (m), 1260 (s), 1170 (s), 1043 (w), 836 (m) 
cm-1 
 
4.3.4 .  (S) -2-Tr i f luoroacety lamino-7-methoxy-
1 ,2 ,3 ,4- terahydronaphthalene (8 )  and (S)-2-
tr i f luoroacety lamino-5-methoxy-1 ,2 ,3 ,4-
terahydronaphthalene  (9 ) .  
The intramolecular Friedel-Crafts alkylation of chloride 6 
(experiment a, Table 1, entry 4) and iodide 7 (experiment b, 
Table 1, entry 8) afforded partly inseparable mixtures of 8 and 9.   
(a) Table 1, entry 4: Chloride 6 (22 mg, 0.071 mmol) was 
dissolved in DCM (5 mL) and added AlCl3 (30 mg, 0.225 
mmol). The mixture was heated to 100 °C in a glass 
pressure tube for 20 h. The mixture was cooled to room 
temperature and then added an aqueous phosphate buffer 
(pH 7, 10 mL, 1 M) and DCM (10 mL). The layers were 
separated and the aqueous phase extracted with additional 
DCM (3 X 10 mL). The combined organic layer was dried 
(MgSO4) and concentrated under reduced pressure. 1H 
NMR analysis of the residue showed a product ratio 8 : 9 
= 83 : 17. The crude product was purified by flash 
chromatography (10% EtOAc in n-pentane). Impure 8 
(7.8 mg, 36% yield, 90% pure, >99% ee) was isolated as 
colorless crystals. The spectroscopic data of 8 was in 
accordance to data reported by Cecchi et al.27 
Enantiomeric excess was determined by chiral HPLC 
analysis (Chiralcel OJ, i-PrOH/n-hexane (1:9), 1.0 
ml/min, 230 nm, tR 25.4 min (S) and 53.8 min (R)). 
Compound 9 was purified by flash chromatography (10% 
EtOAc in n-pentane) up to 70% purity. Data for 9: Rf = 
0.42 (10% EtOAc in n-pentane). 1H NMR  (400 MHz):  
7.13 (app. t, J 8.0 Hz, 1H, H-7), 6.71 (app. d, J 8.0 Hz, 
1H, H-6), 6.70 (app. d, J 8.0 Hz, 1H, H-8), 6.24 (br, 1H, 
NH), 4.40-4.27 (m, 1H, H-2), 3.83 (s, 3H, CH3O), 3.17 
(dd, J 16.2, 5.0 Hz, 1H, H-1), 2.97-2.67 (m, 3H, H-1 and 
H-4), 2.16-2.04 (m, 1H, H-3), 1.94-1.80 (m, 1H, H-3). 13C 
NMR (100 MHz):  157.3 (C-5), 156.7 (app. d, 2JC,F 36.7 
Hz, C=O), 134.1 (C-8a), 126.8 (C-7), 123.9 (C-4a), 121.5 
(C-8), 115.8 (app. d, 1JC,F 288.6 Hz, CF3), 107.7 (C-6), 
55.3 (CH3O), 45.9 (C-2), 35.0 (C-1), 27.5 (C-3), 20.7 (C-
4). HRMS (ESI) calcd for C13H15F3NO2 (M+H)+ 
274.1049, found 274.1053. 
(b)  Table 1, entry 8: Iodide 7 (42 mg, 0.084 mmol) was 
dissolved in DCM (6 mL) and added InBr3 (55 mg, 0.155 
mmol). The mixture was heated to 80 °C in a pressure 
glass tube for 18 h. The mixture was cooled to room 
temperature and added an aqueous phosphate buffer (pH 
7, 10 mL, 1 M) and DCM (10 ml). The layers were 
separated and the aqueous phase extracted with additional 
DCM (3 x 10 mL). The combined organic layer was dried 
(MgSO4) and concentrated under reduced pressure. 1H 
NMR analysis of the residue showed a product ratio 8 : 9 
= 71 : 29. The crude product was purified by flash 
chromatography (10% EtOAc in n-pentane). Impure 8 
(6.4 mg, 26% yield, 93% pure, 97% ee) was isolated as 
colorless crystals.   
 
4.4. Preparation and cyclization of phthalimide protected amino 
alcohol 13 
4.4.1 .  (R)-4-(3-methoxybenzyl ) -1 ,3-oxaz inan-2-one 
(10 ) .  
Tosylate 4 (200 mg, 0.445 mmol) was dissolved in DMSO (10 
mL) and added KOH (120 mg, 2.14 mmol). The mixture was 
stirred at room temperature for 18 h. An aqueous phosphate 
buffer solution was added (pH 7, 5 mL) to quench excess KOH, 
and the solvents were removed under reduced pressure. The 
residue was dissolved in diethyl eter (20 mL) and water (15 mL). 
The layers were separated and the aqueous layer extracted with 
additional diethyl ether (3 x 15 mL). The combined organic layer 
was washed with brine (15 mL) and dried (MgSO4). Purification 
by flash chromatography (EtOAc), yielded 10 (59 mg, 60%) as a 
colorless crystalline material. Data for 10: Mp 80 - 84 °C, Rf = 
0.23 (EtOAc).  D
23 +51.6 (0.50, CH2Cl2). 1H NMR  (400 MHz): 
 7.26 (app. t, J 7.9 Hz, 1H, HAr-5), 6.82 (app. dd, J 7.9, 2.5 Hz, 
1H, HAr-4), 6.77 (app. d, J 7.6 Hz, 1H, HAr-6), 6.72 (app. s, 1H, 
HAr-2), 5.06 (br, 1H, NH), 4.36 (dt, J 11.2, 4.2 Hz, 1H, H-6), 4.22 
(td, J 10.9, 2.8 Hz, 1H, H-6), 3.81 (s, 3H, CH3O), 3.76-3.67 (m, 
1H, H-4), 2.89 (dd, J 12.5, 6.9 Hz, 1H, CHHPh), 2.66 (dd, J 
13.4, 8.7 Hz, 1H, CHHPh), 2.09-1.98 (m, 1H, H-5), 1.86-1.74 
(m, 1H, H-5). 13C NMR (100 MHz):  160.1 (CAr-3), 153.7 (C-2), 
137.5 (CAr-1), 130.1 (CAr-5), 121.4 (CAr-6), 115.1 (CAr-2), 112.4 
(CAr-4), 65.5 (C-6), 55.2 (CH3O), 52.1 (C-4), 42.9 (CH2Ph), 27.5 
(C-5). IR (KBr): 3253 (m), 2939 (m), 1699 (s), 1602 (m), 1584 
(m), 1489 (m), 1434 (m), 1293 (m), 1154 (m), 1092 (m), 1043 
(m), 781 (m), 736 (m) cm-1. HRMS (ESI) calcd for C12H16NO3 
(M+H)+ 222.1125, found 222.1130. 
4.4.2 .  (R)- ter t -Buty l  4-hydroxy-1-(3-methoxy-
phenyl )butan-2-y lcarbamate  (11 ) .  
The title compound was synthesized by adopting a procedure 
described by Ankner and Hilmersson.28 Tosylate 4 (211 mg, 0.47 
mmol) was instantaneous deprotected by the addition of a 
solution of SmI2 (28 mL, 0.1 M, 2.8 mmol) in THF, water (150 
mg, 8.33 mmol) and pyrrolidine (0.46 mL, 5.51 mmol), under 
vigorous stirring. After 5 min, diethyl ether (30 ml) and aqueous 
base (25 mL, 10% wt NaK tartrate + 10% wt K2CO3) was added. 
The layers were separated, and the aqueous phase was extracted 
with additional diethyl ether (3 x 30 mL). The combined organic 
 6
layer was washed with brine (20 mL) and dried (MgSO4). 
Purification by flash chromatography (EtOAc/n-pentane, 25:75 
to 40:60), yielded 11 (44 mg, 32%) as a colorless oil. Data for 11: 
Rf = 0.19 (20% EtOAc in n-pentane). 1H NMR  (400 MHz):  
7.21 (app. t, J 7.9 Hz, 1H, HAr-5), 6.78 (app. d, J 7.9 Hz, 1H, HAr-
4), 6.77 (app. d, J 7.9 Hz, 1H, HAr-6), 6.73 (app. s, 1H, HAr-2), 
4.49 (d, J 8.9 Hz, 1H, NH), 4.10 (m, 1H, H-2), 3.70-3.55 (m, 2H, 
H-4), 3.80 (s, 3H, CH3O), 3.20 (br, 1H, OH), 2.79 (d, J 6.7 Hz, 
2H, H-1), 1.95-1.75 (m, 1H, H-3), 1.70-1.55 (m, 1H, H-3), 1.42 
(s, 9H, t-Bu). 
 
4.4.3 .  (R)-3-Amino-4-(3-methoxyphenyl )butan-1-ol  
hydrochlor ide  (12 ) .  
(a) Hydrochloride 12 was synthesized from the cyclic 
carbamate 10 by adopting a procedure described by Curtis 
et al.29 Cyclic carbamate 10 (360 mg, 1.63 mmol) was 
dissolved in MeOH/H2O (15 mL, 1:1) and added LiOH 
(320 mg, 13.4 mmol). The mixture was under vigorous 
stirring heated to 70 °C for 2 h. The solvent was removed 
under reduced pressure and the crude was dissolved in 
diethyl ether (30 mL) and water (15 mL). The layers were 
separated and the aqueous phase extracted with additional 
diethyl ether (4 x 20 mL). The combined organic layer 
was concentrated under reduced pressure. The residue was 
redissolved in abs ethanol (25 mL) and added conc 
hydrochloric acid (0.5 mL). Removal of the solvents 
under reduced pressure, and attempts with diethyl ether 
trituation, did not yield the expected solid product. 
However, hydrochloride 12 (244 mg, 65%) was isolated 
as a colorless oil and used without further purification. 
Data for 12: 1H NMR  (400 MHz, D2O):  7.37 (t, J 7.8 
Hz, 1H, HAr-5), 7.00-6,93 (m, 2H, HAr-4, HAr-6), 6.92 
(app. s, 1H, HAr-2), 3.84 (s, 3H, CH3O), 3.80-3.59 (m, 3H, 
H-1 and H-3), 3.06 (dd, J 14.1, 6.6 Hz, 1H, H-4), 2.91 
(dd, J 14.1, 8.0 Hz, 1H, H-4), 1.98-1.83 (m, 2H, H-2). 13C 
NMR (100 MHz, D2O):  159.9 (CAr-3), 138.1 (CAr-1), 
131.0 (CAr-5), 122.9 (CAr-6), 115.7 (CAr-2), 113.6 (CAr-4), 
59.0 (C-1), 56.0 (CH3O), 52.2 (C-3), 39.0 (C-4), 34.3 (C-
2). IR (KBr): 2885 (br), 1602 (m), 1489 (m), 1264 (m), 
1156 (m), 1046 (s), 875 (w), 781 (s), 744 (m), 698 (s) cm-
1. HRMS (ESI) calcd for C11H18NO2 (M+) 196.1332, found 
196.1335. 
(b)  Compound 12 was alternatively synthesized from N-Boc-
alcohol 11 by adopting a procedure described by Prashad 
et al.30 N-Boc-alcohol 11 (32 mg, 0.11 mmol) was 
dissolved in toluene (5 ml) and conc HCl (1 mL), and 
heated to 65 ºC for 2 hours. Evaporation of the solid under 
reduced pressure gave 20 mg of 12 (80% yield).      
 
4.4.4 .  (R)-2-(4-hydroxy-1-(3-methoxyphenyl ) -butan-
2-y l ) i so indol ine-1 ,3-dione  (13 ) .  
Phth protection of the amine group in 12 was performed 
according to a procedure described by Liu et al.31 HCl-salt 12 
(108 mg, 0,466 mmol) and phthalic anhydride (100 mg, 0,676 
mmol) was dissolved in toluene (5 mL), and added triethylamine 
(70 L, 0.502 mol). The mixture was heated to 100 °C for 18 h, 
then increasing the temperature to reflux, causing the majority of 
the solvent to distill off. Total reaction time 24 h. The crude 
reaction mixture was dissolved in EtOAc (30 mL), and 
successively washed with aqueous citric acid (10% wt, 20 mL), 
water (20 mL), aqueous NaHCO3 (saturated, 20 mL) and brine 
(10 mL). The organic layer was dried over MgSO4. Purification 
of the crude by flash chromatography (EtOAc/n-pentane, 1:1) 
yielded 13 (65 mg, 43% yield) as a colorless oil. Data for 13: Rf = 
0.28 (EtOAc/n-pentane, 1:1).  D
23 +136.9 (1.0, CH2Cl2). 1H 
NMR  (400 MHz):  7.80-7.71 (m, 2H, Phth), 7.71-7.60 (m, 2H, 
Phth), 7.10 (app. t, J 7.9 Hz, 1H, HAr-5), 6.77 (app. d, J 7.9 Hz, 
1H, HAr-6), 6.72 (app. s, 1H, HAr-2), 6.66 (app. dd, J 7.9, 2.4 Hz, 
1H, HAr-4), 4.81-4.66 (m, 1H, H-2), 3.72-3.63 (m, 1H, H-4), 3.69 
(s, 3H, CH3O), 3.62-3.50 (m, 1H, H-4), 3.40 (dd, J 13.8, 10.0 Hz, 
1H, H-1), 3.12 (dd, J 13.8, 6.3 Hz, 1H, H-1), 2.44-2.28 (m, 1H, 
H-3), 2.12-1.96 (m, 1H, H-3). 13C NMR (100 MHz):  168.8 
(Phth), 159.6 (CAr-3), 139.6 (CAr-1), 133.9 (Phth), 131.6 (Phth), 
129.4 (CAr-5), 123.2 (Phth), 121.2 (CAr-6), 114.1 (CAr-2), 112.4 
(CAr-4), 59.6 (C-4), 55.1 (CH3O), 50.0 (C-2), 38.4 (C-1), 34.7 (C-
3).  IR (thin film, NaCl): 3460 (m), 2934 (m), 1770 (m), 1699 (s), 
1602 (m), 1394 (m), 1263 (m), 1086 (m), 872 (m), 782 (m), 721 
(s) cm-1. HRMS (ESI) calcd for C19H20NO4 (M+H)+ 326.1387, 
found 326.1383. 
 
4 .4 .5 .  Preparat ion  o f  dio l  14  and e ther  15 .  
Cyclization of phthalimide 13 was performed by adopting a 
procedure described by Harris et al.16 Phthalimide 13 (22.8 mg, 
0.070 mmol) was dissolved in dry chlorobenzene (1 mL) and 
added triflic acid (12.5 L, 0.141 mmol). The reaction mixture 
was heated to 80 °C for 4 h. Quenching of the room tempered 
mixture was done by the addition of a phosphate buffer solution 
(pH 7, 10 mL, 1 M). Extraction with DCM (3 x 15 mL), drying 
over MgSO4 and removal of the solvent under reduced pressure, 
resulted in a yellow crude mixture. Isolation of the two main 
products 14 (4.8 mg, 21% yield) and 15 (2.3 mg, 11% yield), 
both colorless oils, was performed by column chromatography 
(5% MeOH in DCM).  
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Fig. 4. Numbering of 14 and 15 with respect to 1H and 13C 
NMR interpretation. 
 
Data for 14: Rf = 0.31 (5% MeOH in DCM). 1H NMR  (400 
MHz):  7.88 (app. d, J 7.7 Hz, 1H, H-12), 7.61-7.55 (m, 1H, H-
11), 7.54 (d, J 8.7 Hz, 1H, H-1), 7.40-7.31 (m, 2H, H-9 and H-
10), 6.74 (dd, J 8.7, 2.6 Hz, 1H, H-2), 6.64 (d, J 2.6 Hz, 1H, H-
4), 5.27 (s, 1H, 12b-OH), 4.69-4.60 (m, 1H, H-6), 3.87-3.64 (m, 
2H, H-14), 3.77 (s, 3H, CH3O), 3.05 (dd, J 15.8, 6.5 Hz, 1H, H-
5), 2.88 (dd, J 15.8, 5.2 Hz, 1H, H-5), 2.29-2.11 (m, 1H, H-13), 
1.94-1.78 (m, 1H, H-13). 13C NMR (100 MHz):  168.4 (C=O), 
159.5 (C-3), 147.8 (12a), 135.3 (4a), 132.3 (C-11), 130.4 (8a), 
129.2 (C-10), 128.5 (12c), 127.7 (C-1), 123.2 (C-9), 123.0 (C-
12), 113.9 (C-4), 112.5 (C-2),  87.1 (C-12b), 68.9 (C-14), 55.3 
(CH3O), 46.5 (C-6), 34.7 (C-5), 34.3 (C-13). Absolute 
configuration (6R, 12bS) was determined by NOESY analysis. IR 
(KBr): 3403 (m), 1682 (s), 1610 (m), 1467 (m), 1389 (m), 1256 
(m), 1111 (m), 1035 cm-1. HRMS (ESI) calcd for C19H20NO4 
(M+H)+ 326.1387, found 326.1395. 
Data for 15: Rf = 0.48 (5% MeOH in DCM). 1H NMR  (400 
MHz):  8.02 (app. d, J 7.4 Hz, 1H, H-12), 7.87 (app. d, J 7.4 Hz, 
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1H, H-9), 7.69 (d, J 8.5 Hz, 1H, H-1), 7.65 (app. t, J 7.4 Hz, 1H, 
H-11), 7.55 (app. t, J 7.4 Hz, 1H, H-10), 6.81 (dd, J 8.5, 2.7 Hz, 
1H, H-2), 6.72 (d, J 2.7 Hz, 1H, H-4), 4.99 (app. t, J 5.4 Hz, 1H, 
H-6), 3.85-3.79 (m, 2H, H-14), 3.80 (s, 3H, CH3O), 3.51 (dd, J 
17.2, 6.8 Hz, 1H, H-5), 2.95 (d, J 17.2 Hz, 1H, H-5), 2.32-2.17 
(m, 1H, H-13), 1.69 (app. d, J 12.0 Hz, 1H, H-13). 13C NMR 
(100 MHz):  166.9 (C=O), 159.6 (C-3), 144.9 (12a), 138.7 (4a), 
131.6 (C-11), 130.4 (8a), 129.8 (C-10), 128.0 (C-1), 124.6 (12c), 
124.1 (C-9), 123.3 (C-12), 112.8 (C-4), 112.8 (C-2),  85.3 (C-
12b), 59.2 (C-14), 55.3 (CH3O), 41.6 (C-6), 34.4 (C-5), 31.1 (C-
13). Absolute configuration (6R, 12bS) was determined by 
NOESY analysis. IR (KBr): 3442 (w), 2919 (m), 1781 (s), 1607 
(m), 1429 (m), 1244 (m), 1036 (m) cm-1. HRMS (ESI) calcd for 
C19H18NO3 (M+H)+ 308.1281, found 308.1292. 
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